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Epigenetic Alterations in Endometrial Cancer and It's Precursors 
Abstract 
Endometrial cancer is a common malignancy of female genital tract. Endometrioid adenocarcinoma 
(EGA) is the most common type of endometrial cancer. Microsatellite instability (MSI) is observed 
in a subset of ECA while chromosomal abnormality or instability is believed to be uncommon event. 
Recently, gene promoter hypermethylation is being increasing recognized as a common and 
important mechanism lead to gene silencing. Information in gene promoter hypermethylation in 
ECA is limited. We aim to investigate methylation status of multiple genes in ECA. In addition, 
endometrial hyperplasia (EH) with or without atypia, which is regarded as precursor lesion of ECA, 
will also be examined. Furthermore, MSI status of ECA is determined, and the possible relationship 
with gene hypermethylation is also assessed. , 
Our study delineated the frequency of methylation of multiple genes in ECA. The genes being 
investigated include ACP, hMLHl, RASSFIA, PRB, PTEN，ATM, MGMT, HICl , E-cad and p i6 . 
The precursor lesion, endometrial hyperplasia, further divided into endometrial hyperplasia with or 
without cytological atypia, and the methylation frequency of multiple genes also be determined. 
The methylation index (ratio or methylated gene over total numbers of gene examined) of ECA, EH 
with atypia and EH without atypia were 0.20, 0.29 and 0.19 respectively. Gene methylation in at 
least one of the genes is common. Our results indicated that gene methylation was also common in 
endometrial hyperplasia. It is suggested that gene methylation may be an early event in 
carcinogenesis of ECA. MSI status of ECA was determined and twenty-six cases (76.5%) were 
microsatellite stable (MSS) and 8 cases (23.5%) were MSI positive. Our study found that MSI 
positive cases correlate with pathological grading and staging of ECA. Interestingly, ECA cases 
with MSI has lower frequency of gene methylation (as assessed by methylation index) as compare 
to microsatellite stable (MSS) cases. The observations suggest that MSI positive and MSS cases 
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Chapter 1 Introduction 
Endometrial cancer is a common malignancy of female genital tract. Majority of 
endometrial cancer are endometrioid adenocarcinoma (EGA). Endometrial hyperplasia 
(EH) is regarded as the precursor lesion of ECA. The association of ECA and EH with 
estrogen is well recognized. However, the carcinogenesis process is still poorly 
understood. A subset of ECA exhibits microsatellite instability (MSI). But it is uncertain 
if there are clinical or patho-biological important differences between ECA with and 
without MSI. In contrast, chromosomal abnormalities, in terms of chromosomal gains or 
loss appear to be uncommon event. Recently, gene promoter hypermethylation is being 
increasing recognized as a common and important mechanism lead to gene silencing. 
Information in gene promoter hypermethylation in ECA is limited. We aim to investigate 
methylation status of multiple genes in ECA. In addition, endometrial hyperplasia, which 
is regarded as precursor lesion of ECA will also be examined. Furthermore, MSI status of 
ECA is also determined and the possible relationship with gene hypermethylation is 
assessed. 
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Chapter 2 literature Review 
2.1 Anatomy and Physiology of Endometrium 
Uterus is a hollow muscular internal female reproductive organ located in pelvis behind 
the bladder and in front of the rectum. The uterus consists of uterine corpus and uterine 
cervix and both fallopian tubes are attached at the corneal region of uterus (Fig 2.1).The 
inner surface of the uterus is lined by endometrium which contains endometrial glands 
among the endometrial stroma. Beneath the endometrium is the myometrium of uterus, 
which consist of thick bundles of smooth muscle cells. The outer surface of the upper part 
of uterus is covered by serosa while the lower part is adventitial tissue. 
p w - M I h B I 
Fig.2.1. The uterus consists of uterine corpus and uterine cervix. Both fallopian tubes 
attached to the corneal regions of the uterus. 
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Fig.2.2 A. The endometrium is divided into the upper functional layer and the lower basal 
layer. The functional layer is sensitive to the hormonal changes while the basal layer is 
relatively in-sensitive to hormonal alterations. (Hematoxylin & eosin stain, original 
magnification X 40) B Higher magnification of the functional layer. In this example is 
secretary type endometrium. (Hematoxylin & eosin stain, original magnification X 200) 
C. Higher magnification of the basal layer, which consists of inactive endometrial glands 
and more closely packed endometrial stromal cells. (Hematoxylin & eosin stain, original 
magnification X 200) 
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Fig.2.3. A. In the first half of the cycle, the endometrium is in proliferative phase. Both 
the endometrial glands and endometrial stroma are proliferative. Mitoic activity is easily 
identified. (Hematoxylin & eosin stain, original magnification X 200) B. After ovulation, 
the endometrium will enter into secretary phase. The endometrial glands become dilated 
and tortoused. The glandular lumen contains secretary material. (Hematoxylin & eosin 
stain, original magnification X 200) 
Endometrium is divided into the upper portion of functional layer and lower portion of 
basal layer (Fig 2.2). The endometrial glands consist of single layered polygonal to 
columnar glandular epithelium. The endometrial stromal cells exhibit oval to spindle 
shape dark stained nuclei with scanty indistinct cytoplasm. In reproductive age, the 
functional layer is very sensitive to hormonal changes and in responds to the cyclic 
changes of estrogen and progesterone levels. The basal layer is relatively insensitive to 
hormonal changes. In the first phase of the cycle, the endometrium in responds to 
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estrogen stimulation and enters into the proliferate phase. Both the endometrial gland and 
stroma become mitotically active and proliferate (Fig 2.3). Ovulation occurs at mid-cycle. 
The endometrium in response to progesterone and enter into the secretary phase. The 
endometrial glands are active in secretary activity and become dilated and tortured (fig 
2.3). If no conception is happened，relating to the lack of hormonal support, the 
endometrium, especially the functional layer start to break down toward the end of the 
cycle and menstruation occur. The residual endometrium, mainly the basal layers will 
then regenerate and enter into proliferative phase of next cycle. However, if there is un-
opposed estrogen stimulation, it will lead to uncontrolled proliferation of endometrial 
glands and resulted in endometrial hyperplasia. Endometrial hyperplasia is considered as 
precursor lesion of endometrioid adenocarcinoma. Endometrial hyperplasia and 
endometrial cancer will be discussed in the subsequent sections. 
2.2 Endometrial cancer 
Endometrial cancer originates in the endometrium of uterus and is one of the most 
common types of female genital tract malignancies. Majority of endometrial cancer are 
adenocarcinoma, and endometrioid adenocarcinoma (ECA) represents the most common 
type. Endometrial hyperplasia (EH) refers to abnormal proliferation of endometrial 
glands and EH is regarded as precancerous lesion of the endometrium and may progress 
to invasive endometrioid adenocarcinoma. 
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2.2.1 Epidemiology of Endometrial Cancer in Hong Kong 
Endometrial cancer is one of the most common cancer of female genital tract and the 8th 
most common cancer of female in Hong Kong. The crude incidence rate is about 10 per 
100,000. Approximately 300 women are diagnosed with endometrial cancer each year in 
Hong Kong. About 30 women die due to endometrial cancer each year. Most (-95%) of 
the endometrial cancers occur in woman age 40 or older with an average age of 55-65. 
(Fig.2.4). 
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Fig.2.4. The age distribution of new cases of endometrial cancer in Hong Kong 
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2.2.2 Etiologies and Risk factors 
For endometrioid adenocinoma (ECA), the association with unopposed estrogen, either 
exogenous or endogenous is well recognized, especially for those cases preceded by 
endometrial hyperplasia (EH). However, there are also cases of ECA without pre-existing 
EH. The association with estrogen with other types of endometrial cancer, which will be 
addressed in later section, is not well established. 
With unopposed estrogen stimulation, the endometrial glands may exhibit abnormal 
proliferation and become hyperplastic, resulted in endometrial hyperplasia (EH). There 
are a spectrum of endometrial hyperplasia. According to the WHO classification, this can 
be divided into 1. simple hyperplasia without cytological atypia, 2. simple hyperplasia 
with cytological atypia, 3. complex hyperplasia without cytological atypia and 4. 
complex hyperplasia with cytological atypia. Simple or complex refer to the architecture 
of the hyperplastic endometrial glands. The risk of the progression to endometrioid 
adenocarcinoma does vary according to the severity of EH: 
Risk of EH progress to ECA 
1. Simple hyperplasia: 1% 
2. Complex hyperplasia: 3% 
3. Simple atypical hyperplasia: 8% 
4. Complex atypical hyperplasia: 29% 
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Endometrial hyperplasia may regress when the unopposed estrogen stimulation is 
terminated or patients received progesterone treatment. However, some EH may progress 
even with medical treatment. The most important determination factor appears related to 
the presence or absence of cytological atypia (Fig 2.5). 
國 
Fig.2.5. The histology of endometrial hyperplasia progress to endometrioid 
adenocarcinoma. A. Simple endometrial hyperplasia without cytological atypia. The 
endometrial glands are more closely packed as compare to normal endometrial glands. 
(Hematoxylin & eosin stain, original magnification X 200) B. Complex endometrial 
hyperplasia with cytological atypia. The glandular architecture is more complex. 
Cytological atypia with rounding up of nuclei, vesicular nuclei and prominent nucleoli 
are shown in the in-box. (Hematoxylin & eosin stain, original magnification X 200) C. 
Endometrioid adenocarcinoma. Complex cribriform malignant glands are formed. 
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Risk Factors (Oncology Channel. 2004) 
Several risk factors have been identified: 
Chronic Estrogen Exposure 
> Obesity 
Studies estimated that women with excess body weight have a 2-5x greater risk of 
developing endometrial cancer. This is likely due to the face that fat cells (adipocytes) 
produce estrogen. 
> Diabetes Mellitus and Hypertension 
The relationship is unclear. Women with a history of diabetes mellitus are 2x more likely 
to develop endometrial cancer. 
> Few or No Children 
Pregnancy is a period of intense progesterone stimulation by the placenta. Progesterone 
counterbalances the growth-stimulating effects of estrogen. 
> Early Menarche and Late Menopause 
Late menopause and early menarche are both associated with more estrogen exposure. 
> Estrogen Replacement Therapy 
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It is believed that the increase in endometrial cancer in the U.S. in the 1970s was due to 
the introduction and widespread use of postmenopausal estrogen therapy that is used to 
relieve the symptoms of menopause. 
> Tamoxifen 
Tamoxifen is an anti-estrogenic drug and is the most widely prescribed hormonal 
treatment for women with breast cancer. However, Tamoxifen is weakly estrogenic 
and one of the side effects is that it induces uterine cancer, especially endometrial 
carcinoma. 
> Diet 
The association between diet and endometrial cancer is unclear. There is some 
evidence to suggest that a diet rich in animal fat and protein puts a woman at a 
greater risk, whereas a diet rich in vegetable, fruits, and whole-grain food reduces 
the risk. 
Previous Cancer 
Women who had history of cancer of the breast, colon, or ovary are at an increased risk 
for developing endometrial cancer. 
Genetic Predisposition 
Some women appear to have a genetic predisposition to endometrial cancer. In some 
families who have an inherited tendency to develop colon cancer called hereditary non-
polyposis colon cancer (HNPCC). Thus this subset of endometrial carcinoma is related to 
microsatellite instability. 
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Factors associated with reduced Risk 
> Tobacco Smoking 
There is some evidence that tobacco smoking actually reduces the rate of endometrial 
cancer. This is likely due to the fact that smokers tend to have lower levels of estrogen 
and a lower rate of obesity. 
> Oral Contraceptives 
Longer use of combined oral contraceptives affords better protection from endometrial 
cancer. The reduced risk is presumably due to the progesterone effects of the 
contraceptives counterbalance estrogen's effect on endometrial cells. 
2.3 Pathology 
Endometrial Cancer 
Majority of endometrial cancers are adenocarcinomas, cancers with differentiation 
toward glandular cells. 
Classification of endometrial carcinoma: 
-Endometrioid adenocarcinoma (about 75 percent) 
-Serous adenocarcinoma (about 5 - 1 0 percent) 
-Clear cell adenocarcinoma (less than 5%) 
Others: including mucinous adenocarcinoma, Squamous cell carcinoma, Mixed 
carcinoma, Undifferentiated carcinoma, Malignant mixed mullerian tumors (MMMT). 
There are less common uterine cancers, including:Stromal sarcomas & Leiomyosarcomas. 
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Fig.2.6. Upper panel. Gross appearance of a case of endometrial cancer. This case 
consists of endometrioid adenocarcinoma, forms a polypoid tumoral mass protruding into 
the endometrial cavity and invades into the underlying myometrium. Lower panel. FIGO 
grade 1 to 3 endometrioid adenocarcinoma (ECA) A. Grade 1. well differentiated ECA B. 
Grade 2. moderate differentiated ECA with solid area. C. Grade 3. poorly differentiated 





Fig.2.7. Serous adenocarcinoma. Serous adenocarcinoma is high grade adenocarcinoma 
and forming distinct papillary architecture with prominent nuclear atypia. A. Low 
magnification displaces the papillary architecture. (Hematoxylin & eosin stain, original 
magnification X 40) B. Higher magnification reveals the presence of small papillary tufts. 
(Hematoxylin & eosin stain, original magnification X 200) C. Prominent cytological 
atypia is evident. (Hematoxylin & eosin stain, original magnification X 400) 
Endometrioid Adenocarcinoma (ECA) (Fig 2.6) 
Endometrioid adenocarcinoma is the most common type of endometrial cancer and 
comprises about 75% of cases. The typical ECA is related to unopposed estrogenic drive 
and often preceded by endometrial hyperplasia. This group tends to be well differentiated 
and occurs in perimenopausal period. Some cases occur in old age, seemingly not related 
to estrogen stimulation and arising in atrophic endometrium. This group less frequently 
well differentiated. There are also some histological variants, including adenosqumaous 
carcinoma, secretary carcinoma, ciliated carcinoma, villoglandular carcinoma and 
Sertoli form carcinoma. 
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Serous adenocarcinoma (Fig 2.7) 
Serous adenocarcinoma, comprises 5 to 10 % of endometrial cancer. It is typically a high 
grade cancer and occurs in elderly. It has the propensity to have prominent myometrial 
and lympho-vascular invasion. 
2.3.1 Grading of endometrial cancer 
Grading of endometrioid adenocarcinoma is according to the International Federation of 
Gynecology and Obstetrics (FIGO) grading system. 
-Grade 1: <5% of non-squamous, non-morular solid growth pattern. 
-Grade 2 : > 5% to 50% of non-squamous, non-morular solid growth pattern. 
-Grade 3: > 50% of non-squamous, non-morular solid growth pattern. 
The presence of notable cytological atypia, which is more marked as compare to the 
grade, the grading can upgrade for one grade. 
For serous adenocarcinoma is always considered as high grade cancer. The grading of 
other types of carcinoma is less well established. 
2.3.2 Staging of endometrial cancer (Cancerlinks, 2003) 
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Endometrial cancers are staged according to the approved system in 1988 by the 
International Federation of Gynecology and Obstetrics (FIGO). Factors used to stage the 
disease include the depth of the myometrial invasion, whether the tumor has spread to the 
cervix and other nearby organs, whether it has metastasized to the lymph nodes or distant 
metastasis. 
Stage 1: 
la - tumor is restricted to endometrium, 
lb - it invades less than one half of the myometrium. 
Ic - it invades more than one half of the myometrium. 
Stage 2: 
2a - invades cervical glands. 
2b — invades cervical stroma. 
Stage 3: 
3a - uterine serosa is affected and/or adnexa (tubes and ovaries) or there are tumor cells 
found in the abdomen. 
3b - tumor extends to vagina, upper two thirds. 
3c - lymphatic nodes are affected, paraaortal or pelvic. 
Stage 4: 
4a - urinary bladder and/or intestines (rectum) are affected. 
4b - abdominal or inguinal lymphatic nodes are affected. 
15 
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Fig.2.8. The different stages of endometrial cancer, (canerlinks, 2003) 
2.4 Prevention and Treatment 
The prognosis is largely depending on grading and staging of cancer. The average 5-year 
survival rates for endometrial cancer are 90% for Stage I, 60% for Stage II，40% for 
Stage 111, and 5% for Stage IV. (cancerlinks, 2003) Early detection is the best prevention 
from developing invasive endometrial cancer. Endometrioid adenocarcinoma may 
proceeded by endometrial hyperplasia. Patient with endometrial hyperplasia may present 
with abnormal vaginal bleeding. The diagnosis of endometrial hyperplasia may be confirmed by endometrial sampling or uterine dilati n and cur ttage (D & C). Thus, early
16 
treatment of the endometrial hyperplasia by progesterone containing medication or 
endometrial resection may prevent the progression of disease to invasive endometrioid 
adenocarcinoma. 
The treatment of endometrial cancer depends on the stage of the disease and the general 
condition of patients. It includes surgical excision, hysterectomy with or without 
radiation and chemotherapy. Hormonal therapy may also be used. 
2.5 Molecular alterations in endometrial cancer 
The carcinogenesis pathway may be different among different subtypes of endometrial 
cancer. Endometrioid adenocarcinoma (EGA) represents the most common type of 
endometrial cancer and serous adenocarcinoma represents a small subset but having 
aggressive clinical behavior. It was suggested that these two types of endometrial 
carcinoma not only have different clinical behavior, but also the carcinogenetic 
mechanisms are also different. According to Deligdisch and Holinka, they proposed there 
are two types of endometrial carcinoma (Berchuck A., 1997). Type I is endometrioid 
adenocarcinoma (EGA) which is estrogen-dependent and appears mostly in pre- and peri-
menopausal women, it is well differentiated, early stage and therefore having favorable 
prognosis. Most of the endometrial cancers are typical endometrioid adenocarcinomas 
(EGA). 
Type II is non-endometrioid adenocarcinoma. In general, it is estrogen independent, 
diagnosed mostly in postmenopausal women. They are associated with older age, poor 
differentiation, greater risk for metastases, advanced stage, and hence unfavorable 
prognosis. 
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The molecular alterations associated with type 1 and type 2 endometrial carcinomas 
appears different (Berchuck A., 1997). These molecular features are illustrated in table 
2.1. 
Table 2.1. Clinical and Molecular Features of Endometrial Carcinoma 
II Type I II Typejl 
Clinical Features 
Risk factors Unopposed estrogen||Age 
Race l l ^ t e > Black jWhite = Black 
Degree of differentiation Well-differentiated Poorly 
differentiated 
Histology Endometrioid Nonendometrioid 
[stage ||l/II ijjjl/IV — 
Prognosis Favorable |Unfavorable 
Molecular Features'^ 
Ploidy iDiploid yAneuploid 
K-ras overexpression ||Yes ||Yes 
HER-2/neu overexpression No ||Yes 
p53 overexpression ||Yes 
F f l N mutations ||Yes ||NO 二 
Microsatellite instability ||Yes 
2.5.1 Genetic alterations in endometrial cancer 
The molecular events involved in the carcinogenesis of endometrial carcinoma are poorly 




Oncogene activation in endometrial cancer 
H E R - 2 /腳 
The WR-Hneu gene encodes for a tyrosine kinase receptor that is activated following 
binding of the ligand heregulin (Berchuck A.，1997). Several studies suggest that this 
oncogene product is overexpressed in 10 to 15% of endometrial cancers (Lukes A.S., et 
al, 1994; Monk B.J.，et al, 1994; Wang D.，et al, 1995; Khalifa M.A., et al, 1994). 
Herzel and co-workers, (Hetzel D.J., et al.’ 1992.) in an immunohistochemical analysis of 
247 patients with endometrial cancer, observed 15% strong staining, 58% mild staining, 
and 27% no staining. The 5-year progression-free survival was 56% for the strong 
staining, 83% for the mild staining, and 95% for the nonstaining groups. Strong 
overexpression was associated with a poor (51%) overall survival. 
Likewise, Lukes and co-workers (Lukes A.S., et al, 1994) found high expression in 12% 
of patients. Overexpression was more common in stage III and IV patients (24%) than in 
stage I or II patients (6%) and was associated with poor progression-free survival in 
univariate analysis. 
Ras 
The ras family of G-proteins (N, H，K-ra^) play a critical role in the regulation of cellular 
proliferation (Berchuck A., 1997). The most frequent site of mutation of the Y^-ras 
oncogene in endometrial carcinoma is codon 12. Y^-ras mutation is detected in 
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endometrial carcinoma, but this does not appear associated with survival in endometrial 
cancer (Enomoto T.，et al, 1993; Duggan B.，et al., 1994; Sasaki H., et ai, 1993). 
2.5.1.2Tumor suppressor genes inactivation 
Tumor suppressor genes are inactivated by mutation, LOH or epigenetic alterations such 
as promoter hypermethylation. 
Tumor suppressor genes may be divided into two groups: 
1. Growth regulating tumor suppressor gene (regulating cell growth or apoptosis) 
2. DNA repair type tumor suppressor gene (DNA damage recognition and repair) 
Tumor suppressor genes (Table 2.2) such as p53, APC, and INK4a appear to have active 
roles in regulating cell growth and/or apoptosis, the DNA damage recognition and repair 
genes can arguably be viewed as having roles in controlling growth. Inactivation of DNA 
mismatch repair activity likely contributes to cancer via an increased frequency of 
mutations in other cellular genes, particularly genes that are rate-determining in tumor 
development. The DNA mismatch repair genes appear to be inactivated in a considerable 
subset of sporadic cancers, including roughly 10 to 20% of colorectal, endometrial, and 
gastric cancers. 
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Table 2.2. A list of tumor suppressor genes 
Gene Cancers associated Presumed function of protein 
GSTP-1 Breast, prostate cancer It encodes the detoxification protein glutathion-S-
transferase placental enzyme 1 
APC Colorectal cancer, Regulates levels of jS-catenin protein in cytosol 
desmoid tumors binding to microtubules 
MGMT Colon, lung, pancreas 06-methylguanine-DNA methyltransferase, DNA 
cancer repair enzyme 
p 15 Gastric cancer An inhibitor of cyclin-dependent kinase 4，which is 
an important mediator of cell cycle control, especially 
in the pathway stimulated by TGF-/3，DAPK, is 
involved in apoptosis. 
p l6 Approx. 25-30% of Cyclin-dependent kinase inhibitor (i.e., Cdk4 and 
many different cancer Cdk6) 
types, Breast, bladder, 
lung cancer and 
leukemia 
E-cad Gastric (Diffuse type), Cell-cell adhesion molecule, potential invasion and 
lobular breast metastasis suppressor 
carcinoma, rare in other 
type, e.g., ovarian 
SOCS-1 Gastric cancer, Suppressor of cytokine signaling, a component in IL-
hepatocellular 6 pathway inhibit STAT3 phosphorylation through 
carcinoma (HCC) direct interaction of Jak2 
HIC-1 Breast, colon, brain Hypermethylated in cancer, a transcriptional 
cancer repressor to suppress cell growth 
HLTF Colon cancer Helicase-like transcription factor, a SWI/SNF family 
protein 
PRB Endometrial, breast Progesterone receptor B, response to estrogen and 
cancer progesterone which has antiproliferative effect. 
ATM Breast cancer Atactic telangiectasis mutation gene effect on 
apoptosis response. 
PTEN Glioma, breast, Phosphoinositide 3-phosphatase; protein tyrosine 
prostate, follicular phosphatase. A dual-specificity phosphates that 
thyroid carcinoma, negatively regulates the phosphoinositol-3-
head and neck kinase/Akt pathway and mediates cell cycle arrest 
squamous carcinoma and apoptosis. 
TIMP-3 Colon, breast, lung Tissue inhibitors of metalloproteinases 
cancer 
RASSFIA Bladder, breast, head Encoding RAS-binding proteins located at 3p21.3 
and neck cancer function to inhibit tumor growth 
DAPK Colon, lung, head and A pro-apoptotic calcium-regulated serine/threonine 
neck cancer kinase, is involved in apoptosis. 
hMLHl Colorectal, gastric, DNA mismatch repair 
I endometrial 
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2.5.1.2.1 Mutation and loss of heterozygosity (LOH) of tumor suppressor genes in 
endometrial cancer 
p53 
p53 is a tumor suppressor gene that is important to control the mechanism of apoptosis 
when DNA is damaged (fig.2.9). Molecular data from multiple studies support the 
hypothesis of different genetic pathways in the development of endometrioid and serous 
carcinoma. p53 mutation occurs during progression of about 10-20% of endometrioid 
carcinomas, but not occurring in endometrial hyperplasiais. (Lax S.F., 2004) It is 
considered a late event. In serous carcinoma, p53 mutation is the most frequent genetic 
alteration, followed by inactivation of p l6 and e-cadherin and amplification ofher2/neu. 
p53 mutation occurs in endometrial intraepithelial carcinoma, the putative precursor of 
serous carcinoma. (Lax S.F., 2004) 
Mutations in the p53 tumor suppressor gene leading to overexpression of mutant p53 
protein are the most common molecular alterations described in human cancers to date. 
(Berchuck A., 1994) Between 4 and 49% of endometrioid carcinomas and 71.4 and 100% 
of serous carcinomas (Caduff R.F., 1996; Inoue M.，1994; Manek S., 1996; Tashiro H.， 
1997) overexpress p53 protein. Of note, p53protein overexpression has been 
demonstrated in 10 to 15% of early-stage disease and 40 to 50% of advanced-stage 
disease, (Berchuck A., 1994; Kohler M.F., 1996) but does not occur in endometrial 
hyperplasia (Berchuck A.，1994; Kohler M.F., 1993; Sherman M.E., 1995). This suggests 
that p53 mutation may be a late event in the tumorgenesis of endometrial carcinoma or 
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that acquisition of a p53 mutation leads to the development of a virulent endometrial 
cancer that does not pass through a phase of hyperplasia as postulated by Berchuck and 
co-workers. (Berchuck A., 1997; Lax S.F., 2004) Several studies have demonstrated a 
positive association between p53 overexpression and high nuclear grade and FIGO stage, 
though these have not been universal findings. (Save V.，1998; Yamauchi N.，1996) In 
addition, overexpression of p53 is independently associated with poor survival. For 
example, Kohler and co-workers (Kohler M.F., 1996) observed a median survival of 6.1 
years in patients whose tumors did not overexpress p53 in comparison with a median 
survival of 1.4 years in patients whose tumors overexpressed p53. 
Mitogenic Signals DNA Damage 
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Figure 2.9. DNA damage signals (e.g., ionizing and UV radiation, hypoxic stress, etc.) 
activate p53 through multiple signaling pathways (Sherr CJ.，1998) 
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PTEN 
PTEN (phosphate and tensin homologue deleted on chromosome ten) is a candidate 
tumor suppressor gene that has been isolated from the 10q23-24 region. (Burton J.L., 
1998) It is a dual-specificity phosphates that negatively regulates the phosphoinositol-3-
kinase/Akt pathway and mediates cell cycle arrest and apoptosis. Risinger and co-
workers (Risinger J.I., 1997) identified PTEN mutations in 34% of 70 endometrial 
carcinoma specimens. The tumors in which PTEN was mutated did not have a unique 
clinical phenotype. Loss of heterozygosity and mutations in the PTEN (MMACl) tumor 
suppressor gene are frequent in endometrial carcinoma. 
APC 
APC is a large gene, with 15 exons (Fig.2.10) encoding a 2843 residue large protein that 
appears to serve several functions. First, APC may negatively regulate the Wnt-1 
signaling pathway by binding to p-catenin. Mutated APC product, unable to bind, allows 
cytoplasmic and nuclear accumulation of p-catenin, with persistent activation of 
downstream transcription and growth factors (fig.2.11). APC protein also colocalizes 
with the microtubule cytoskeleton, leading to speculation that APC is involved in cell 
migration and cell adhesion. Finally, APC might be involved in cell cycle regulation or 
perhaps even apoptosis. 
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Figure 2.10. Schematic representation of APC protein domains and mutation analysis. 
Germline mutations in the APC gene (predominantly chain terminating) are dispersed 
throughout the 5' half of the sequence, with two apparent 'hot spots' at codons 1061 and 
1309. Somatic mutations in the APC gene appear to cluster in a region termed the 
'mutation cluster region,' and mutations at codons 1309 and 1450 are most common. 
(AbeloffMD) 
The APC protein has been found to bind to a number of proteins, including (3-catenin, y-
catenin，glycogen synthase kinase 3p (GSK3p), EBl, hDLG, microtubules, and the 
related proteins axin and conductin. (Kinzler K.W., 1996; Bienz M., 1999) Several lines 
of evidence imply that APC has a critical function in regulating P-catenin. (Bienz M., 
1999; Willert K., 1998) 
The truncated APC proteins present in many colorectal cancers lack some or all of the 
repeat motifs crucial for binding to p-catenin. APC is mutated and unable to bind and/or 
effectively coordinate the regulation of (3-catenin, p-catenin accumulates in the cell, 
complexes with transcription factors of the Tcf (T-cell factor) or Lef (lymphoid enhancer 
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factor) family, such as Tcf-4, and translocates to the nucleus (Fig. 2.11). Though somatic 
mutations in APC appear to be rare in cancers arising outside the colon and rectum, 
(Kinzler K.W., 1996) oncogenic mutations in P-catenin's N-terminus have also been seen 
in a significant fraction of many different cancer types, including melanoma, 
hepatocellular cancer, endometrial cancer, and endometrioid-type ovarian cancer. 
(Polakis P., 1999) c-MYC and cyclin Dl，other Tcf/p-catenin targets with increased 
expression as a result of APC or p-catenin mutations presumably promote cell growth 
and/or inhibit cell death. Further work on APC function should offer crucial insights into 
the development of cancers, as well as novel strategies and targets for chemotherapy and 
perhaps even chemoprevention. 
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Fig.2.11. A model indicating the function of the APC in the regulation of p-catenin (P-cat) 
(A) In normal cells, GSK3P，APC, and axin function to promote degradation of free 
cytosolic P-cat, probably as a result of phosphorylation of the N-terminal sequences of P-
cat by GSK3P. GSK3P activity and P-cat degradation are inhibited by activation of the 
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wingless (Wnt) pathway, as a result of the action of the Frizzled receptor and dishevelled 
(DSH) signaling protein. (B) Mutation of APC in colorectal and other cancer cells results 
in accumulation of p-cat, binding to Tcf-4, and transcriptional activation of Tcf-4 target 
genes, such as c-MYC, cyclin Dl, MMP-7, and PPARd. (Fearon ER. 1997.) 
In endometrial cancer study, no APC mutations were detected, but LOH at the APC locus 
was found in 24.3% ECs. (Moreno-Bueno G, 2002) 
2.5.2 Epigenetic Alterations 
DNA methylation leads to transcriptional repression. This process involved the 
integration of DNA methylation with chromatin organization and the regulation of 
histone and other protein and eventually acetylation (Baylin and Herman, 2000; Jones 
and Baylin, 2002). DNA methylation represses genes transcription by recruitment of the 
methyl-CpG-binding protein MeCP2, which in turn recruits a histone deacetylase activity. 
This was supported by the finding that DNMT can form complex with histone 
deacetylase (HDACl and HDAC2) and other transcriptional repressor (Fuks, et a l , 2000; 
Fuks，et a l , 2001; Robertson, et al., 2000a). HDAC can remove acetyl groups from the 
amino terminal core of the histone tails which are critical modulators of chromatin and 
rendering the sequence inaccessible to the transcriptional machinery (Jones and Baylin, 
2002; Robertson, 2002). 
The link between genetic changes and epigenetic alterations was found that PML-RARa 
(Promyelocytic leukemia-retinoic acid receptor a ) fusion protein in PML cells induces 
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the transcriptional repression and the aberrant methylation of the promoter of a candidate 
RAR transcriptional target, RAR /3. The PML-RAR transcriptional repression was due to 
temporally distinct recruitment of DNMT and HDAC. This report provided inside for the 
specific DNA methylation pattern observed in certain tumor types (Di Croce，et al., 2002) 
The presence of DNA methylation in cancer was initially thought to be a global 
hypomethylation of genome that lead to massive overexpression of oncogenes whose 
CpG islands were normally hypermethylated (Feinberg and Vogelstein, 1983). 
Subsequent finding showed that DNA methylation lead to transcriptional suppression of 
tumor suppressor genes in cancer, thus suggesting that DNA hypermethylation of tumor 
suppressor gene is more important in the development of cancer (Jones and Laird, 1999). 
Several studies have investigated the role of DNA methylation in tumorgenesis. First, 
5'methylcyctosine was subjected to spontaneous deamination to thymidine. This C to T 
transit mutation in CpG dinucleotides in the coding region of tumor suppressor genes are 
hotspots for mutation (Zingg and Jones, 1997). 24% of point mutations in p53 in human 
cancer are due to this phenomenon (Greenblatt, et a l , 1994). Second, increased DNMTs 
activities may lead to cell transformation. The consequence of it was aberrant 
hypermethylation of promoter region of tumor suppressor gene. It was supported by the 
fact that dense methylation in CpG islands of the promoter in tumor tissues was absent in 
the corresponding normal tissues (Jones and Baylin, 2002). And methylated genes can be 
reactivated by demethylating agent, 5' aza-cytidine (Bender, et al., 1998). Third, the 
selective advantage for gene function loss is the same for promoter methylation or 
inactivating mutation 
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2.5.2.1 CpG islands methylation 
In human genome, methylation takes place at the 5' position of cytosine base of a CpG 
dinucleotide resulting in the formation of 5-methylcytosine. It is an enzyme-mediated 
chemical modification that add methyl groups to the C-5 position of the cytosine rings, 
resulting in formation of 5-methylcytosine (5-mCyt). This unstable base is finally 
deaminated to Thymine (T). Between 60-90% of the cytosine at CpG dinucleotide are 
methylated under physiological normal condition (Bird, A.P., 1986). On the other hand, 
cytosines that are found in a clustering of CpG rich sequence of 0.5-4 kb in length, 
namely CpG islands are typically unmethylated. CpG islands are defined by having a GC 
content over 0.5 and frequency of occurrence of CpG site over 0.6 in a minimum of 200 
bp (Gardiner-Garden and Frommer, 1987). In human, there are about 45,000 CpG islands 
representing 1% of the whole genome (Antequera and Bird，1993). These areas can be 
found in the proximal promoter regions of about 50% of human genes and are normally 
protected from methylation (Antequera and Bird, 1993; Bird, 2002). On the other hand, 
methylated CpG islands can be found in the promoters of silenced alleles for selected 
imprinted autosomal genes, inactived X-chromosomes (Surani, 1991)，aging tissues as 
well as in cancer cells (Toyota and Issa, 1999). 
2.5.2.2 De novo methylation 
De novo methylation of 5' CpG islands is a rare event in normal somatic tissue. In 
addition to imprinted genes and inactive X-chromosomal genes, methylation can be 
found in aging and cancer tissues which is supported by the fact that global increase in 
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CpG island was observed in tissue culture cells and cancer cells (Antequera, et al., 1990; 
Feinberg, et al.,1998; Jones and Laird, 1999). 
Although the mechanism of de novo methylation is still not clearly understood, the recent 
discovery of DNA methyltransferases (DNMT) seems to be responsible for this process. 
3 types of DNMT were identified, namely DNMTl，DNMT2 and DNMT3 (Robertson, 
2002). DNMTl was the first enzyme to be isolated as a mammalian DNA 
methyltransferase. Study found that modest overexpression of exogenous mouse DNMTl 
in NIH3T3 cells can promote cellular transformation (Wu，et al., 1993). In another study, 
genetic inactivation of DNMTl in mice decreased the intestinal tumors development 
(Laird, et a l , 1995). These finding supported the role of DNMTl in tumorgenesis. 
DNMT2 was discovered in an attempt to identify novel putative DNMT in mammalian 
cells (Okano，et al., 1998b). However, no methyl-transfer activity of DNMT2 gene 
product was reported using in vitro assay (Okano, et al., 1998b). 
The presence of de novo methyltransferase activity in DNMTl inactivated embryonic 
cell supported the notion that other DNMT might exist (Lei, et al., 1996). DNMT3a and 
DNMT3b were identified by EST database searches using the conserved 
methyltransferase domain (Okano, et al., 1998a). Disruption of DNMT3a and DNMT3b 
genes in mice caused severe embryonic defect (Okano, et a l , 1999). This model 
suggested that DNMT3a and DNMT3b are responsible for establishing de novo 
methylation that are maintained by DNMTl. Studies showed that expression of human 
DNMT3a and DNMT3b gene was elevated in several tumor cell lines suggesting that 
these 2 DNMT might be actively involved in tumorgenesis (Rhee, et a l , 2002; Robertson, 
et a l , 2002b). 
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2.5.2.3 Detection of gene promoter hypermethylation 
In this study, methylation specific PGR (MSP) was used as the methylation analysis 
method. Beside MSP, gene promoter hypermethylation can be studied by other different 
methods. 1. combined bisulfite restriction analyses (COBRA) which constitute a specific 
approach releasing on the creation or modification of a target for restriction endonuclease 
after bisulfite treatment; 2. methylation-sensitive single nucleotide primer extension (Ms-
SnuPE) which employs bisulfite/PCR combined with single-nucleotide primer extension 
to analyse DNA methylation status quantitatively in a particular DNA region without 
using restriction enzymes; 3. bisulfite sequencing which is the direct means to detect 
cytosine methylation in bisulfite treated DNA; 4. southern blotting analysis which 
employs methylation-sensitive restriction endonuclease to analyse the methylation pattern 
in certain restriction sites of the CpG islands. This method does not require bisulfite 
treatment but it require large amount of genomic DNA for analysis. Also, promoter 
hypermethylation can by studied by genomic approach such as methylation-sensitive 
arbitrarily primed PGR (MS-AP-PCR) or restriction landmark genomic scanning (RLGS). 
Since MSP is a sensitive, specific method and relatively simple method, we employed 
MSP as detection method for gene methylation in our study. 
2.5.2.4 Epigenetic alterations in endometrial cancer 
Cancer is often viewed as a genetic process in which the developing cancer cell acquires 
successive mutational lesions through the activation of proto-oncogenes or inactivation of 
tumor-suppressor genes. However, in the previous study, the comparative genomic 
hybridization results demonstrated that the number of chromosomes involved in genomic 
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alterations in EACs was distinctively fewer than those in other types of tumor. (Hirasawa 
A, 2003; Tritz D, 1997). Both frequency and patterns of LOH differed greatly between 
the two tumor types. Although LOH was frequently detected in the non-endometrioid 
adenocarinomas, it was rare in the endometrioid adenocarinomas. LOH was detected in 
only 8 of the 18 endometrioid adenocarinomas, with chromosomes 17, 13，and 2 being 
the most frequently affected (22%, 20%, and 19%, respectively). (Tritz D, 1997) In 
contrast, LOH was detected in all cases of non- endometrioid adenocarinomas, with 
chromosomes 17p, 14，and 12 showing the highest LOH (83%, 77%, and 40%, 
respectively). (Tritz D, 1997) These tumor types are likely caused by different 
tumorigenic pathways that reflect alterations of different cancer-controlling genes. (Tritz 
D, 1997) So carcinogenesis of endometrial cancer may be due to another mechanism 
rather than chromosomal mutation and deletion. Epigenetics is an alternative or 
complementary mechanism to mutational events in oncogenesis. Epigenetic events are 
heritable, non-mutational alterations in gene function that are mediated by factors other 
than changes in primary DNA sequence. Epigenetic mechanisms of gene silencing, 
including promoter hypermethylation of tumor suppressor genes, have been shown to 
contribute to tumorigenesis. Gene promoter hypermethylation is now the most well 
recognized epigenetic changes in human cancers. Therefore, epigenetic alterations were 
investigated in endometrial cancer in this study. 
Gene promoter hypermethylation is believed to be as common as the inactivation of 
tumor suppressor gene by mutation and LOH (Jones and Baylin, 2002). It is also 
considered as the alternative mechanism in the "Knudson two-hits" hypothesis (Jones and 
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Laird, 1999). The list of candidate tumor suppressor genes that are silenced by promoter 
methylation in certain cancer is growing rapidly. In the following sections, epigenetic 
alteration especially DNA methylation in endometrial cancer will be reviewed. 
Epigenetic mechanisms that result in aberrant gene expression are a prominent feature of 
many cancer types. One main epigenetic mechanism for gene silencing involves promoter 
hypermethylation. Type I and type II endometrial cancers exhibit differ clinical, histology 
and molecular genetic characteristics. We hypothesize that these differences also extend 
to epigenetic phenomena. Promoter methylation analysis of a panel of genes in 
endometrial cancers, suggested that promoter hypermethylation may occur more 
frequently in type 1 than type II endometrial carcinoma (Risinger JI，et al, 2003). These 
data tend to support the hypothesis that type I and type II endometrial cancers will exhibit 
distinct patterns of gene silencing based on promoter hypermethylation events. 
E-cadherin 
E-cadherin (E-cad) is a cell-cell adhesion molecule, potential invasion and metastasis 
suppressor. In a study, all normal endometrium and endometrial hyperplasia showed no 
methylation of the E-cadherin gene with preserved positive staining of E-cadherin. In 
endometrial carcinoma, methylation of E-cadherin was detected in subset of endometrial 
carcinoma and was associated with degree of tumor differentiation and myometrial 
invasion. In G1 EC, 66.7% showed positive staining and 15.6% methylation of the E-
cadherin gene (fig.2.12). In G2 tumors, 19.0% showed positive staining and 50.0% 
methylation of the E-cadherin gene. In G3 tumors, 9.1% showed positive staining and 
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81.8% methylation of the E-cadherin gene. Of the samples with no-myometrial invasion, 
23.1% had methylation. In those with invasion in less than half of the myometrium, 
28.6% did and in those with invasion of half or more of the myometrium, 55.6% had 
methylation. Of samples that did not have lymph node metastasis, 33.7% had methylation, 
whereas of samples that had lymph node metastasis, 60.0% had methylation. (Saito T，et 
al, 2003) 
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pl6 regulates Cdk4 activity which is a critical factor in regulating pRb phosphorylation. 
Inactivation of p i r e s u l t s in inappropriate phosphorylation of pRb and a subsequent 
inability of hyperphosphorylated pRb to bind E2Fs and appropriately regulate gene 
expression at the Gl/S transition and contribute to tumorigenesis. The pl6 genomic 
structure and mutations is shown in fig 2.13. 
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Fig2.13 Genomic structure, mutations, and transcripts of the INK4a (pi 6) locus. Genomic 
deletions, point mutations (arrows), and promoter methylation (arrowheads) noted in 
human cancers. (Haber DA, 1997; Abeloff MD) 
In endometrial cancer studies, partial pl6INK4A deletions were found in 8% of ECs. 
(Semczuk A, 2003). From 4.2% to 34% of ECs exhibited aberrant promoter methylation. 
(Semczuk A, 2003; Chao H, 2000). Normal endometrium(NE) displayed no methylation 
and showed normal expression of the p l6 mRNA. 17% of atypical hyperplasia (EAH) 
was shown to have hypermethylation o f p l 6 gene and pi6 methylation was hypothesized 
to be an early event of endometrial carcinogenesis and is associated with the progression 
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of endometrial carcinoma (Chao H, 2000). pl6INK4A alterations were generally 
accompanied by gene silencing, confirmed by aberrant protein immunostaining. 
Hypermethylation is highly correlated with inhibition of pl6 gene transcription. There 
was a significant difference in the frequency of pl6INK4A alterations between early 
(stage I) and advanced (stages II-IV) ECs (Semczuk A, 2003). 
PTEN 
Apart from mutation, PTEN promoter methylation (19%) is also relatively common in 
endometrial carcinoma. It is also reported to be associated with metastatic disease 
(Salvesen H.B., 2001) 
PRB 
Progesterone response is dependent on the presence of functionally intact progesterone 
receptor (PR). Progestin-induced activity is only initiated when the steroid is bound to the 
PR. An absence of hormone response will result from either the absence of the PR or its 
failure to bind the PR. Point mutations or total deletions in the steroid binding domain of 
the PR can occur results in inactive receptor. In humans, PR is composed of two 
progesterone-binding proteins, PRA and PRB. The expression of the human PR is 
reported to be controlled by two promoters that direct the synthesis of mRNA transcripts 
encoding the two receptor proteins. The PRA is N-terminally truncated by 164 amino 
acid residues and therefore is slightly smaller than PRB. The PRA and PRB co-express in 
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the same cells and appear to be synthesized in equal proportions. But they appear to be 
functionally different (E. McGowan, 1999). 
In endometrial cancer study, the results suggest that only PRE is inactivated. PRE was 
methylated, whereas PRA was all unmethylated. In 83 cancerous and 33 normal samples, 
75% ECs had only methylated alleles ofPRB that was well correlated with negativity in 
immunohistochemical staining for PRB. Treatment with a demethylating agent, 5-aza-2'-
deoxycytidine, restored PRB expression in all cell lines, suggesting that inactivation of 
this gene is through methylation. (Sasaki M, 2001) 
APC 
In endometrial cancer, APC promoter lA hypermethylation was observed in 43% to 
46.6% of ECs, and was associated with the endometrioid phenotype and microsatellite 
instability. (Moreno-Bueno G, 2002; Zysman M, 2002). 
MSH2 and MLHl 
The protein products of the MSH2 (chromosome 2p) and MLHl (chromosome 3p) genes 
appear to have critical roles in the recognition and repair of DNA mismatches (Fig. 2.14). 
Once the cell acquires impaired mismatch repair function, for instance, as a result of 
inactivation of either MSH2 or MLHl, hundreds of errors/mutations may arise and fail to 
be repaired during each cell division cycle. Because many of the mutations arise in 
mononucleotide, dinucleotide, and trinucleotide repeat tracts (i.e., microsatellite sequence 
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tracts) scattered throughout the genome, it has also been termed the microsatellite 
instability (MSI) phenotype. 
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Fig2.14. Mismatch repair pathway in human cells, (a and b) During DNA replication, 
DNA mismatches may arise (c) The mismatch is recognized by MutS homologs, MSH2 
and GTBP/MSH6, MSH3 may substitute for GTBP/MSH6 in some cases, (d and e) MutL 
homologs, such as MLHl and PMS2, are recruited to the complex and the mismatch is 
repaired through the action of a number of proteins, including an exonuclease, helicase， 
DNA polymerase, and ligase (Kinzler KW, 1996) 
A study investigated the region 700 bp upstream of MLHl covering 48 CpG sites. In 
endometrial cancer, 29% of ECs were fully methylated (over 80% of CpGs are 
methylated) (Kanaya T, 2003), 25% were partially methylated (10-80%) and 46% were 
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not methylated (less than 10%) (Kanaya T, 2003). Among methylated cancers, 42% 
contained methylated promoters in their normal endometria adjacent to carcinoma with 
profiles similar to those of cancer lesions (Kanaya T, 2003), 7% cases of atypical 
endometrial hyperplasia coexisting endometrial carcinoma had hMLHl promoter 
hypermethylation (Miturski R, 2003). These findings suggest that hypermethylation of 
the MLHl promoter is frequent in the histologically normal endometrium adjacent to 
cancers, supporting the notion that hypermethylation of mismatch repair genes is the 
initial step that triggers various genetic events in endometrial carcinogenesis. And these 
were associated with the MSI phenotype (Kanaya T, 2003). 91% cases of endometrial 
carcinoma (EC) displaying MSI had hMLHl promoter hypermethylation (Miturski R, 
2003; Esteller M, 1999). Loss of hMLHl and hMSH2 expression was reported in 25% 
and 18% of ECs，respectively (Miturski R, 2003), but it did not correlate with the known 
clinicopathological variables of cancer. In addition, no obvious correlation was found 
between methylation and the lack of hMLHl and hMSH2 protein expression in human 
uterine tumors. The results showed that DNA methylation may influence tumor 
progression, but they are not directly associated with the inactivation of the mismatch-
repair machinery in ECs. (Miturski R, 2003) 
2.5.2.5 Promoter methylation of tumor suppressor genes in other cancers 
RASSFIA 
RASSFIA is located in 3p21. RASSFIA was isolated as a tumor suppressor gene in this 
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region from a two-hybrid screen (Dammann, et al.，2000). One of the slice variants of the 
gene RASSFIA undergoes frequent epigenetic changes in tumors of lungs, nasopharynx, 
breast, kidney, stomach, ovary and urinary bladder (Agathanggelou, et al., 2001; Burbee, 
et al, 2001; Byun, et al, 2001; Dreijerink, et al, 2001; Lee, et al, 2001; Lo，et a l , 2001; 
Yoon, et al., 2001). Although the functions of RASSFIA are not completely understood, 
several studies found that it can reduce tumor growth both in vitro and in nude mice 
model (Burbee, et al, 2001; Dreijerink, et al., 2001; Vos, et al, 2000). Those experiments 
suggested that it was a candidate tumor suppressor gene. Structural analysis also found 
that its RAS-association domain likely in the RAS-mediated apoptotic mechanism. 
RASSFIA was also showed to bind with NOREl, the novel RAS effecter and MSTl, the 
pro-apoptotic protein kinase in mediating the apoptotic effecter of RAS (Khokhlatchev, et 
al, 2002; Ortiz-Vega, et al, 2002). 
HIC-1 
In 90 Cervical cancer (CC) cases, a high frequency of promoter methylation in HIC-1 
gene was found. Correlation of promoter methylation with clinical characteristics and 
other genetic changes revealed the following: a) overall promoter methylation was higher 
in more advanced stage of the disease, b) the HICl promoter methylation was frequently 
seen in association with microsatellite instability. Promoter methylation was associated 
with gene silencing in CC cell lines. Treatment with methylation or histone 




The DNA repair protein 0^-methylguanine DNA methyltransferase (MGMT) removes 
alkyl adducts from the O^ position of guanine in DNA. Failure to remove the alkyl 
adducts generate G:C to A:T transition mutation and promote tumorgenesis as 
demonstrated (Esteller, et a l , 2001). MGMT which located at 10q26, is frequently 
hypermethylated in human cancers resulting in loss of expression (Bae, et al, 2002, 
Esteller, et al, 2002, Oue, et al, 2001). 
ATM 
The Ataxia-telangiectasia-mutated (ATM) gene is located on chromosome llq22-23 
(Gatti R.A.，1988; Lange E.，1995; Savitsky K.，1995)，it's gene product is a protein 
kinase belonging to the PI3 kinase family. Multiple phosphorylation substrates have been 
identified including p53, MDM2, and BRCAl, proteins involved in DNA repair and cell 
cycle checkpoint control. ATM-dependent modifications of p53 result in the induction of 
apoptotic mediators. ATM is a tumor suppressor that plays a role in maintenance of 
genomic stability. 
It is believed that ATM promoter is a target for epigenetic silencing in cultured tumor 
cells. Aberrant methylation of the ATM promoter occurs in 25% of head and neck 
squamous cell carcinomas (Ai L.，2004). The presence of methylated ATM promoter 
shows a statistically significant correlation with an earlier age of initial diagnosis and 
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decreased overall survival, particularly in early-stage tumors. These findings indicate that 
ATM promoter hypermethylation occurs in head and neck squamous cell carcinoma, and 
this feature is a potentially useful prognostic marker in this tumor type. 
2.5.3 Microsatellite instability (MSI) 
Microsatellites are short, highly repetitive DNA tandem repeat (usually 1-6 base pair) 
sequences found throughout the genome. (Eshleman J.R., 1996) They are usually, but not 
always, noncoding sequences. Two of the most common sequences are repeats of (A)n 
and (C) where n = 10-60 distributed throughout the genome. These sequences contribute 
much of the polymorphisms seen in the human genome shows variation between 
individuals (Weber and May, 1989) and can be used as markers in genetic analysis. 
Despite the high degree of polymorphisms between individuals, the patterns of 
microsatellites within a given individual are stable. 
The change of any length in these repetitive sequences due to insertion or deletion in 
tumor tissue as compared to normal is called microsatellite instability. Microsatellite 
instability can be detected by the PGR. Analysis using primers at the boundaries of 
known microsatellites will produce two bands on gel electrophoresis with each band 
representing one parental homologue in informative cases. In the replication errors 
phenotype, the size of the bands will be increased or decreased when compared to the 
bands obtained from PGR of genomic DNA from normal tissues. It is now recognized 
that the patterns of microsatellites are unstable in many tumors as manifested by 
expansions and contractions of these sequences. These sequences are believed to be error 
prone due to their monotonous nucleotide repeats. It is theorized that during DNA 
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replication, there is slippage of DNA polymerase in these repetitive sequences that leads 
to addition or deletions of bases that are not detected by the proofreading activity of the 
polymerase. These errors are detected, excised, and repaired by a complex of mismatch 
repair proteins. 
Many studies found MSI is important and has significant role in carcinogenesis, it occurs 
in both hereditary and sporadic form of various organs including stomach, lung, breast 
and prostate (Caldes, et al.，2000; Hayden, et al.，2000; Perinchery, et al., 2000; 
Yamashita, et a l , 2000). MSI is one of the major mechanisms of cancer susceptibility. It 
was first observed in hereditary nonpolyposis colorectal cancer (HNPCC) and also later 
observed in sporadic colorectal carcinoma (Aaltonen, et al” 1994; Liu, et a l , 1996; 
Peltomaki, et a l , 1993).and has been identified in 17 to 43% of endometrial carcinomas. 
(M.H. Wallace, 1998; A. Horii, 1992; H. Itoh，1994; Y. Hattori , 1996; S. Akimoto , 
1998; Taniguchi K., 1998) The sporadic endometrial carcinomas displaying 
microsatellite instability were mainly stage I adenocarcinomas (Taniguchi K.，1998) .In a 
large fraction of MSI + cancers, inactivation of the MLHl gene may occur via epigenetic 
changes, such as DNA methylation of MLHl transcriptional regulatory sequences. 
(Leung S.Y.，1999; Cunningham J.M.，1998; Herman J.G., 1998; Kane M.F.，1997; 
Markowitz S.，1995) MSI is showed to be related to hMLHl methylation. (Whelan AJ, 
2002) Also, MSI was correlated with histological grade, International Federation of 
Gynecologists and Obstetricians (FIGO) stage, myometrial invasion, and lymphonode 
metastasis. (Hirasawa A, 2003) 
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In MSI study, several MSI markers were commonly used in MSI status detection. It was 
a panal of 7 markers, including both mononucleotide (BAT25, BAT26, BAT40) and 
dinucleotide repeats (D2S123, D5S346, D17S250, TGF/32R). This panel contained 
markers from the standard panel of the National Cancer Institute (NCI) recommendation 
(Boland at al., 1998). This panal was used in previous colorectal cancer studies and 
showed highly sensitive in MSI detection. 
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Chapter 3 Objectives of study 
We aim to investigate the epigenetic alterations in endometrioid adenocarcinoma (ECA) 
and its' precancerous lesion endometrial hyperplasia. In addition, microsatellite status of 
ECA will also be determined. The possible relationship between methylation status, MSI 
status and clinical-pathological features of ECA will be assessed. 
1. Gene promoter hypermethylation study in endometrioid adenocarcinoma 
To delineated the occurrence and frequency of methylation of multiple genes in 
endometrioid adenocarcinoma (ECA) and endometrial hyperplasia. We examined the 
promoter hypermethylation of 10 candidate tumor suppressor genes in ECA. The 
relationship between methylation status and tumor grade and stage will be assessed. 
2. Microsatellite status analysis in endometrioid adenocarcinoma. 
We examined the MSI status with 7 markers in ECA. The relationship between MSI 
status and, tumor grade and stage will be assessed. 
3. Correlation between MSI and promoter methylation analysis 
To assess the possible relationship between methylation status and microsatellite 
instability status in ECA. 
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Chapter 4 Materials and Methods 
4.1 Samples 
4.1.1 Formalin fixed paraffin embedded tissues. 
Samples are retrieved from the archival tissue bank from the Anatomical and Cellular 
pathology Department, CUHK. Formalin fixed, paraffin embedded tissue blocks were 
used. These include: 
-Endometroid adenocarcinoma (ECA) samples were obtained from 34 cases of 
endometrioid adenocarcinoma (ECA) which included 6 cases of ECA co-existing with 
endometrial hyperplasia and 28 cases without co-existing endometrial hyperplasia. 
- 8 cases of Serous adenocarcinomas (SCA) 
- 2 1 cases of endometrial hyperplasia without atypia (EH) 
-21 cases of endometrial hyperplasia with atypia (EAH) 
-12 Cases of normal endometrium were used as control (including 4 cases in proliferative 
phase, 4 cases in secretary phase and 4 cases in inactive phase) 
4.1.2 Cell lines 
Endometrial cancer cell lines RL-95 and KLE were obtained from American Type 
Culture Collection, Rockville, MD. Cell lines RL-95 was grown in 1:1 mixture of 
Dulbecco's modified Eagle's medium and Ham's F12 medium with 1.2g/L sodium 
bicarbonate and 0.005mg/ml insulin. KLE was grown in 1:1 mixture of Dulbecco's 
modified Eagle's medium and Ham's F12 medium with 1.17g/L sodium bicarbonate and 
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l.OmM sodium pyruvate. All cell lines were supplemented with 10% fetal bovine serum 
(FBS) (Sigma, St Louis, MO), lOOU/ml penicillin and 10 // g/ml streptomycin and 
maintained in log phase growth in an incubator with humidified atmosphere of 5% CO2. 
4.2 Histological grading and staging of samples 
All samples were stained with hematoxylin and eosin (H&E) and the histological 
assessment was performed by an experienced pathologist. All ECA were FIGO staged 
and graded. 
4.3 Microdissection on tissue sections. 
Microdissection is a technique that can precisely identify and specifically select groups of 
the cells for molecular analysis. It has been used to separate the mixed cellular 
components of tumor and loci of varied differentiation in carcinomas. This is particularly 
useful when the cellular content in the specimen of interest is low. The ratio of tumor 
cells to normal contaminant is critical in molecular analysis, particularly in methylation 
and microsatellite studies. 
15 serial Sfim sections were cut from formalin-fixed, paraffin-embedded blocks and the 
first was stained with hematoxylin and eosin as reference slides examined under the 
microscope. The tumor areas were marked with a marker pen for localizing the tumor of 
interest. The other slides were placed one by one beneath the reference slides, and the 
areas of interests were similarly marked. The slides were kept moist all the time and the 
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tumor tissues were scraped out under a microscope using fine needles. Normal 
endometrium tissues were excluded. 
4.4 Extraction of nucleic acid 
4.4.1 Extraction of DNA from paraffin embedded tissues 
The dissected tissue pellet was resuspended in 200|al tissue lysis buffer and 40/zl of 
20/xg/ml proteinase K and incubated at 55°C until complete digestion of the samples. 
DNA was extracted from endometrial cancer microdissected paraffin tissues by High 
Pure PGR Template Preparation Kit (Boehringer Mannheim, Indianapolis, IN) according 
to the manufacturer protocol. 200|il of binding buffer was added and incubated at 72°C 
for 10 minutes. The reaction mixture was then mixed with 100|al isopropanol. The 
reaction mixture was transferred to a High Pure Filter column and centrifuged at 8000 
rpm for 1 minute. The flow through was discarded and 500|al washing buffer was added 
to the column followed by centrifugation at 8000rpm for Imin. this procedure was 
repeated. Finally the column was combined to a new 1.5ml tube and DNA was eluted 
with 200^1 MilliQ water. The concentration of DNA was measured by a UV-
spectrophotometer (Pharmacia) and stored in -20°C. 
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4.4.2 Extraction of DNA from cell lines 
All cell lines were grown in 90mm tissue culture plate with 10 ml medium. For DNA 
extraction, to obtain cell pellet, medium was discarded and cells were washed 3 times by 
cold Ix PBS in the culture plate. Tissue pellet was resuspended and DNA was extracted 
by High Pure PGR Template Preparation Kit (Boehringer Mannheim, Indianapolis, IN) as 
above. 
4.5 DNA methylation analysis 
The technique of methylation specific PGR (MSP) was used to detect methylated DNA. 
4.5.1 Overview of Methylation-Specific PGR (MSP) 
MSP is a breakthrough in speed and sensitivity for gene methylation analysis. The 
procedure takes advantages of bisulfite-mediated chemical conversion of cytosine to 
uracil, followed by PGR using primers designed to distinguish methylated from 
unmethylated DNA. Advantages of MSP are that it avoids the use of restriction enzymes 
and problems of incomplete enzymetic digestion; it is very sensitive, the sensitivity is up 
to 0.1% methylated alleles of a given CpG island locus, permitting the analysis of small 
and heterogeneous samples, it requires only small amount of DNA; it is specific for 
relevant CpG sites; it is not prone to false-positive results and it can be performed on 
paraffin-embedded samples. 
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4.5.2 Bisulfite modification of DNA 
Bisulfite modification allows for let methylated and unmethylated primer designed for 
MSP distinguish between methylated and unmethylated DNA. DNA from paraffin tissues 
and cell lines was modified using CpGenome DNA modification kit (Intergen Company, 
Purchase, NY). Sodium bisulfite converts all unmethylated cytosine residues to uracil 
while methylated cytosine residues are unaltered in this process. After sequence 
conversion, methylation specific PCR is employed to detect these using primers specific 
for any gene of interest. 
DNA modification was carried out by adding l|ig DNA in 99|il MilliQ. DNA was 
denatured using 0.2M NaOH at 37°C for 10 minutes. 550ml of DNA modification 
reagent 1 (Intergen Company) was added to denatured DNA incubated at 50°C for 20 
minutes. The modified DNA was purified by incubating with 750|il and 5ml DNA 
modification reagent 2 and 3 (Intergen), respectively, at room temperature for 10 minutes. 
The reaction mixture was spun at SOOOrpm for 1 minute followed by discarding the 
supernatant. The pellet was washed with 1.0ml 70%ethanol, vortexed and spun at 5000 
rpm for 10 minutes. The supernatant was removed. The washing steps were repeated for 
3 times. Modification was completed by incubated with 50|al of 20mM NaOH with 
90%ethanol for 5 mins followed by centrifugation at 5000 rpm for 1 min. the modified 
DNA was precipitated with 1 ml 90% ethanol and centrifiiged at 5000 rpm for 10 mins. 
The modified DNA was stored at -20°C for future use. 
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4.5.3 Methylation-Specific PCR (MSP) 
Two of bisulfite modified DNA were amplified in a total volume of 25|il containing 
Ix PCR buffer2 (Applied Biosystems)，2mM Mg CI2, 0.25mM dNTP, of each 
primer and lU of AmpliTag Gold polymerase (Applied Biosystems) at 95°C for 10 mins, 
35 cycles of 95°C for 45 sec, the specific annealing temperature for 45 sec and 72°C for 
45 sec, followed by a final extension of 72°C for 10 mins. In-vitro methylated DNA (IVD) 
(Intergen, purchase, NY) was used as a positive control for methylation and water was 
used as a negative control. 10|il of PCR products were loaded onto nondenaturing 10% 
polyacrylamide gels. Gels were stained with ethidium bromide, and visualized under UV 
illumination. 
In this part of study, we have examined the promoter hypermethylation of 10 candidate 
tumor suppressor genes in endometrial cancer (ECA) and its precursor lesions, 
endometrial hyperplasia with atypia and without atypia, by MSP. Table 4.1 summarized 
the function of these 10 tumor suppressor genes. 
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Table 4.1 Function of 10 tumor suppressor genes investigated. 
Gene Cancers associated Presumed function of protein 
APC Colorectal cancer Regulates levels of /3-catenin protein in cytosol binding to 
microtubules 
MGMT Colon, lung, pancreas 06-methylguanine-DNA methyltransferase, DNA repair 
cancer enzyme 
hMLHl Colorectal, gastric, DNA mismatch repair 
endometrial 
p l 6 Approx. 25-30% of Cyclin-dependent kinase inhibitor (i.e., Cdk4 and Cdk6) 
many different cancer 
types, Breast, bladder, 
lung cancer and 
leukemia 
E-cad Gastric (Diffuse type), Cell-cell adhesion molecule, potential invasion and 
lobular breast metastasis suppressor 
carcinoma, rare in 
other type, e.g., 
ovarian 
HIC-1 Breast, colon, brain Hypermethylated in cancer, a transcriptional repressor to 
cancer suppress cell growth 
PRB Endometrial, breast Progesterone receptor B，response to estrogen and 
cancer progesterone which has antiproliferative effect. 
ATM Breast cancer Atactic telangiectasis mutation gene effect on apoptosis 
response. 
PTEN Glioma, breast, Phosphoinositide 3-phosphatase; protein tyrosine 
prostate, follicular phosphatase. A dual-specificity phosphates that negatively 
thyroid carcinoma, regulates the phosphoinositol-3-kinase/Akt pathway and 
head and neck mediates cell cycle arrest and apoptosis. 
squamous carcinoma 
RASSFIA Bladder, breast，head Encoding RAS-binding proteins located at 3p21.3 function 
and neck cancer |to inhibit tumor growth 
All the primer sequences and annealing temperatures were listed in table 4.2 
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Table4.2 Primer sequences and MSP conditions. 
Marker Primer Sequence I Temp.(°C)~| 
E-cadherin "m F: T T A G G T T A G A G G G T T A T C G C G T 57 
(Herman, et R： TAACTAAAAATTCACCTACCGAC 
al, 1996) u F: TAATTTTAGGTTAGAGGGTTATTGT 53 
R: CACAACCAATCAACAACACA 
Pl6 ~M F: TTATTAGAGGGTGGGGCGGATCGC ^ 
(Herman, et R: GACCCCGAACCGCGACCGTAA 
al, 1996) u F: TTATTAGAGGGTGGGGTGGATTGT 60 
R: CAACCCCAAACCACAACCATAA 
” h M L H l ~ F : ACGTAGACG TTT TATTAGGGTCGC ^ 
(Fleisher, et R： CCTCATCGTAACTACCCGCG 
al, 1999) u F: TTTTGATGTAGATGTTTTATTAGGGTTGT 58 
R: ACCACCTCATCATAACTACCCACA 
RASSFIA F: GTGTTAACGCGTTGCGTATC ^ 
(Lo, et al, R: AACCCCGCGAACTAAAAACGA 
2001) u F: TTTGGTTGGAGTGTGTTAATGTG 60 
R:AAACCCCACAAACTAAAAACAA 
MGMT ^ 
心 te l ler et al M F: TTTCGACGTTCGTAGGTTTTCCG 
1999a) ‘ R: GCACTCTTCCGAAAACGAAACG 
U F: TTTGTGTTTTGATGTTTGTAGGTTTTTGT 60 
R: AACTCCACACTCTTCCAAAAACAAAACA 
APC ^ 
心 te l ler et al M F: TAT TGC GGA GTG CGG GTC 
� 2 0 0 0 ) ’ R: TCGACGAACTCCCGACGA 
U F: GTG TTT TAT TGT GGA GTG TGG GTT 60 
R: CCAATCAACAAACTCCCAACAA 
^ M: F: TGA TTG TCG TTC GTA GTA CG ^ 
(Sasaki, M., R: CGA CAA TTT AAT AAC ACG CG 
2001) U: F: TGA TTG TTG TTT GTA GTA TG 55 
R: CAA CAA TTT AAT AAC ACA CA 
FTEN M: F: TTTAGCGTTTGTGAGTAGTCGC ^ 
(Kiyoshi Sato, R: CCTTCCCTTTCAAAAAAAACCG 
2002) U F: GTTTAGGTGAGGGAGATGAGAGAT 56 
R: CACCTTCCCTTTCAAAAAAAACCA 
ATM M: F: TCC AAT ATC ACG CGA TCT CC ^ 
(Designed by R: CGA AGG GCG AGT CGT AAA C 
Lo, K.W., u： F: TCC AAT ATC ACA CAA TCT CCA CA 62 
CUHK) R： GGA GTT TGA GTT GAA GGG TGA G 
m ^ M: F: TTCGGGTTAGGGTCGTAGTC ^ 
(Strathdee, et R: CTAACGGAAAACTAT 
al. 2001) I I 
4.6 Microsatellite Analysis 
Microsatellites (Tautz, 1989) are highly polymorphic DNA markers that include small 
arrays of di-，tri- and tetra-nucleotide tandem repeats, e.g., (CA)n/(TG)n, with repeat size 
of 1-6 base pairs and are interspersed throughout the genome (Weber and May, 1989). 
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The size of microsatellite is highly variable or polymorphic, ranging around a mean of 
100 base pairs. These sequences are not transcribed into RNA, the function and formation 
mechanism of these repeats are unclear. 
PCR-based methods can detect allelic abnormalities in the genome of cancer patients, 
such as loss of heterozygosity deletion, microsatellite instability and gene loss in cancer. 
This approach relies on an individual being heterozygous at a specific genetic locus, such 
as at a microsatellite, where the number of tandem repeats is often polymorphic. A 
heterozygous individual will have one number of repeats at the locus on one chromosome, 
and a different number at the same locus on the other chromosome 
Tumor tissue from a cancer patient who is heterozygous at a particular locus (termed as 
informative individual) can be analyzed using PGR, and is compared with normal tissue 
that has been analyzed in the same way. If one of the alleles that is present in the normal 
DNA of the heterozygous individual is missing from the DNA of the tumor calls, the 
tumor is said to have undergone a reduction to homozygosity or loss of heterozygosity 
whereas subtle alterations in number of nucleotide repeats within microsatellites in tumor 
cell compared to normal one results in microsatellite instability. 
34 Cases of paired normal and tumor tissues were used to determine the microsatellite 
instability (MSI) status. A panal of 7 markers, including both mononucleotide (BAT25, 
BAT26, BAT40) and dinucleotide repeats (D2S123，D5S346, D17S250, TGF|82R), was 
examined. The microsatellite markers are fluorescent based. This panel contained 
markers from the standard panel of the National Cancer Institute (NCI) recommendation 
(Boland at a l , 1998). The primer sequences, annelealing temperatures and estimated 
length of PGR products for each locus was obtained from Genome Data D Base. The 
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primers were labeled with florescence and analyzed on urea-polyacryamide gel according 
to standard protocol (Leung et al.，2000). Microsatellite instability (MSI) was 
demonstrated by the presence of new fragments of variable size in tumor DNA. The 
tumors were classified as high-level MSI (MSI-H) if >30% of loci displayed instability, 
low level MSI (MSI-L) if <30% of loci displayed MSI, or microsatellite stable (MSS) if 
no loci displayed MSI (Boland at al., 1998) 
PCR or multiplex PGR examinatioin was performed in reaction volumn 25|il containing 
Ix PCR buffer2 (Applied Biosystems)，2mM Mg CI2, 0.25mM dNTP，5[iM of each 
primer and lU of AmpliTag Gold polymerase (Applied Biosystems) at 95°C for 10 mins, 
35 cycles of 95°C for 45 sec, the specific annealing temperature for 45 sec (table 4.3) and 
72�C for 45 sec, followed by a final extension of 72°C for 10 mins. PCR products were 
separated by electrophoresis in 4% polyacrylamide gell with 6M urea on an ABI PRISM 
377 automated DNA sequencer. Paired up normal and tumor samples were loaded into 
consecutive lane which contained overlapping alleles of the same lane. Two fluorescent-
labeled dyes, FAM and HEX were displayed on the ABI PRISM 377 as blue and green 
colour respectively. The data collected was analyzed using GeneScan analysis software 
v3.1 (Applied Biosystems). 
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Table 4.3 Primer sequences and PCR conditions for MSI analysis 
Primer Primer sequence (5，-3，) Temperature (�C) 
BAT-25 Hex-TCG CCT CCA AGA ATG TAA GT 50°C Touch Down 
TCT GCA TTT TAA CTA TGG CTC 
BAT-26 Hex-TGA CTA CTT TTG ACT TCA GCC W C 
AAC CAT TCA ACA TTT TTA ACC C 
D5S346 Fam-ACT CAC TCT AGT GAT AAA TCG G G 5 5 � C 
AGC AGA TAA GAC AGT ATT ACT AGT T 
D2S123 Fam-AAA CAG GAT GCC TGC CTT TA 55°C 
GGA CTT TCC ACC TAT GGG AC 
D17S250 Fam-GGA AGA ATC AAA TAG ACA AT 54°C Touch Down~~ 
GCT GGC CAT ATA TAT ATT TAA ACC 
BAT-40 Fam-ATT AAC TTC CTA CAC CAC AAC 54°C Touch Down 
GTA GAG CAA GAC CAC CTT G 
TGF/32R Fam-CTT TAT TCT GGA AGA TGC TGC 5 0 T 
GAA GAA AGT CTC ACC AGG C 
4.7 Statistical analysis 
The significance of the correlation between MSI, staging and grading were tested by 
Spearman test, and that of the correlation between MSI and methylation index was tested 
by Mann-Whitney test. All statistical analysis was performed by SPSS software, version 
10.0 (SPSS, Inc). A two side P value of less than 0.05 was considered statistically 
significant. 
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Chapter 5 Results 
5.1 Clinical-pathological features of endometrioid adenocarcinoma. 
The mean age of patients was 55.7 +/- 10.6 years old (range from 38 to 78). All ECA 
were FIGO staged and graded and the histological assessment was performed by an 
experienced pathologist. Among the 34 cases, 52.9% were FIGO grade 1，26.5% grade 2 
and 20.6% grade 3; 61.8% were FIGO stage I, 11.8% stage II and 26.5% stage III. Tumor 
grade correlate with stage. (Spearman p=0.002) The correlation between grading and 
staging of patients were shown in table 5.1 . 
Table 5.1. The relationship between grading and staging of patients (Spearman p=0.002) 
i I I I m I T -
Grade | 1 | 15 | 1 | 2 ~~~18 
\ ~ 2 I 5 I 1 I 3 9 
I 3 I 1 I 2 I 4 7 
xSad I 21 I 4 I 9 M 
5.2 Promoter hypermethylation in endometrial cancer 
Ten tumor-suppressor genes were analyzed in 34 ECA which include 6 cases of ECA 
coexisting with hyperplasia, 8 SCA, 21 EAH, 21 EH and 12 normal endometrium by 
MSP. These include pl6, hMLHl, E-Cadherin (E-Cad), RASSFIA，MGMT, ATM, 
PTEN, PRB, APC, HICl. The MSP results were shown in 10% acrylamide gel stained 
with ethidium bromide (Fig.5.1). In ECA samples, the methylation frequency is 44% in 
hMLHl , 35% in RASSFIA, 26% in E-Cad，21% in MGMT, 15% in PRB and ATM, 
12% in APC, 9% in p l 6 and HICl, and no methylation was detected in PTEN. The 
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methylation frequency in individual cases of ECA, SCA, EAH and EH were shown in 
table 5.2 and table 5.3. The methylation frequency of each gene were summarized in 
table 5.4. We compared the methylation pattern of these genes between endometrial 
adenocarcinoma (ECA) and its precancerous lesions (EH and EAH) and serous 
adenocarcinoma (SCA) (fig. 5.2), and 2 groups of ECA were compared and analyzed (fig 
5.3). The differential increase in methylation frequencies from hyperplasia to cancer was 
found in E-cad, APC and MGMT, while interestingly, PTEN had differential decrease in 
methylation frequency. In contrast, hMLHl had comparable methylation frequencies in 
cancer and hyperplasia. Concurrent methylation of multiple genes appears common in 
both hyperplasia and cancer. The methylation index in EH, EAH and ECA were 0.19， 
0.29 and 0.20，respectively. It indicated that gene methylation occurs in endometrial 
hyperplasia and may be an early event in carcinogenesis of ECA. Twelve normal 
endometrium controls did not show any aberrant hypermethylation in all these genes by 
MSP. 
By comparing 2 groups of ECA, ECA co-existing with hyperplasia and ECA without co-
existing with hyperplasia showed difference in methylation frequency. However, the 
distinct difference between 2 groups of ECA in pattern of methylation frequency cannot 
be found and not significant. 
By comparing 2 types of ECs. Interestingly, for the Serous adenocarcinoma (SCA) which 
is non-endometrioid adenocarcinoma, no methylation was detected. However, 
methylation is common in endometrioid adenocarcinoma (ECA). 
The correlation between promoter hypermethylation and clinicopathologic parameters 
was investigated. The distribution of gene promoter hypermethylation and staging and 
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grading of ECA were shown in table 5.5 and table 5.6 respectively. There was no 
statistically significant association was found between the methylation status of the genes 
and the clinical pathological parameters. 
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Table 5.2. The methylation of individual markers and the methylation index (MI) in 
individual cases of ECA. For the first 6 cases, they are endometrioid adenocarcinoma 
coexisting with hyperplasia. (+ methylation; - no methylation. For cases of endometrioid 
adenocarcinoma with co-exist endometrial hyperplasia, the results were listed as 
carcinoma / hyperplasia.) 
"stage Grade CA+H Head pl6 hMLHl rassfla I APC I PRB I PTEN fflCIl ATM MGMT MI 
"7b i i +/- -/+ “ -/+ _-/+ -/+ -I- -/- -/+ +/- +/- 0.3/0.5 
lA 1 2 ~ -I- 一+1- +/- — -I- ~ ~ -I- "-/- -I- -/- 0.3/0 
IB 1 "1 -/- -/- +/- -/- "+/- -I- "-/- -I- - -I- "T" 0.2/0 
I a ~ 1 "4 1+ ~~7- -/- "+/- -/- "-/- -/- - -I- ~7- 0.2/0.1 
"Ic i 5 7 - - / - +/+ — -/- -/+ -I- -/+ -I- +/- -/+ 0.2/0.4 
"IF" 1 ~6 7 T~ +/- ~ ~ -/- -I- ~ - / - --I- 0.1/0.1 
PRB PTEN m e n ATM MGMT MI 
~TB i 7 - - - + - + - ； ： ； 0.2 
IC 1 8 - ~ ~ - ~ - _ ： ： 0-1 
"TB~ 1 ‘ 9 — - ~ - - 一 - “ + 0 - 1 _ 
1 B i 10 “ - ~ - - ~ ~ + 0 . 1 _ 
1 B i 11 “ r ~ - - “ - ： o j _ 
"Tb 1 12 - - + + - + - ； ： ： 0.3 
i 13 I + I - - - - - - + 0.2 
l A l 14 - + + - - - + 0.3 
IB 1 15 — - ~ ~ + " + - + + ： 0-4 
2B 1 — 1 6 . - - _- ~ - + ： 0-1 
3C 1 17 I + + - - + ； - 0.3 
2B ~ 18 + ~ ~ ~ - — + - - - - - - 0.2 
IA i 19 ~ - - - ~ ~ + 0 .2_ 
3C 2 — 2 0 • - - - - ~ 0.1 
IB 2 ~ 21 . - - ~ - - ： ： 0 
IB 2 ~ 22 .+ - "- ~ + - ： ： 0.2 
3C 2 — 2 3 + ~ ~ + _ - - - - + 0.3 
IC 2 ~ 24 � - "- ~ - ： ： 0 
IB 2 — 2 5 - ~ ~ + + - - - - - + 0.3 
3C ~2 26 ~ - - + - - + - - - - 0.2 
1b~~ 2 H + - - " + ~ 0.2 
I b ~ ~ 3 - 28 ~ + - - ： O j _ 
3A 3 ~ 29 + + _ + - - - - 0-3 
3C "1 30 — - ~ ~ + + + - - - 0.3 
IB ~3 31 — - ~ ~ + ； - + - - - - 0.2 
3A 3 ~ 32 ‘ + - "• ： ： 0.1 
2B 3 ~ 33 - "- - - - ： 0 
"IA 3 34 I - I - I - I + - - - - I - - 1 0.1 
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Table 5.3. The methylation of individual markers and the methylation index (MI) in 
individual cases of SCA, EAH and EH. +methylation; - no methylation. 
~~SCA Ecad pl6 hMLHl rassfla APC PRB PTEN HICIl ATM MGMT MI 
1 - - - - - ； ； ： ： - 0 
2 - — - - - - - ； ： ： - 0 
3 - - - - - ： - ； - - 0 
4 - - — - - - - - - — - 0 ~ 
5 - - - - - - ： ： - 0 
6 - — - - - - ； ： ： ： 0 
7 - - — - - - - - - - - 0 
8 一 - - - - - ； - - ； ： 0 
~ Ecad pl6 “ hMLHl rassfla ~ A P C PRB PTEN— HICIl ATM ~MGMT M I ~ 
1 I - “ - - + + + ； - ； 0.3 
2 - - + - + - - - + 0.3 
3 - - - + - - + - - ； 0.2 
4 . + + - - - - - - 0.2 
5 — - - - ： ： ： ： ： ： ： 0 
6 + - + + - - + - - - 0.4 
7 + - - - - - - + - - 0.2 
g I I + + + - + ；; + 0.5 
9 + - + - 0.2 
10 + - - + - + ； + + - 0.5 
n + - - - + - 0.2 
12 I I I + - + - + - - 0.3 
13 + - - - + - 0.2 
14 + - - + + - 0.3 
15 + - - + - - - + - + 0.4 
16 I I + + - - - + + - 0.4 
17 I I I + - - - + + - 0.3 
18 I I I - “ - + - - + + 0.3 
19 - . - - - - - - + 0.1 
+ + - - - - + ； 0.3 
Yl I I + + + + - - + - 0.5 
Ecad— pl6 hMLHl TassHa J^jgj^ 
1 . + + - - + - - - 0.3 
2 + + - - - - + ； - ；; 0.3 
3 + + - - + ； - ； 0.3 
4 I + I I - - + - ；; - 0.2 
5 _ + - - - - - - - 0.1 
6 I I + I - - + - ； ； 0.2 
- J . - - - - - - - - - 0 
g + - - - - ；; 0.1 
9 I I + I - - + - ： ： 0.2 
10 + + - - - - - ；; 0.2 
n I I + + — - - - - ； + 0.3 
12 - + + + - - + - - - 0.4 
13 I I + I + - + - ； ；; 0.3 
- + i Z I _ - - — - - - 0.1 一 
15 - - - - - - - - - 0 
16 + I I I I + + - ； - 0.3 
yj + I + I _ + - - ； + 0.4 
18 + - - - - - - - ： ： 0.1 
1 9 - - - - - - - - - - 0 
^ - - - 0 
21 - • - - - - I - + 0.1 
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APC E-cad 
B B B H E H I B S S S B m Q Q Q Q m 
M U M U M U M U M U M U + - - M U M U M U M U M U M U + - -
ECA22 ECA/H3 EAH2 EH1 N ECA7 EC A/HI EAH6 BH1 N 
P16 MGMT 
B D D B B B I D S I D B D I 
M U M U M U M U M U M U + — — M U M U M U M U M U M U + - -
ECA11 ECA/H2 EAH1 AH1 N ECA7 ECA/H5 EAH1 EH11 N 
PRB RASSF1A 
m m ^ l l l l l Q I Q j j l l l 2 j 2 B B B H 9 l 
M U M U M U M U M U M U + - - M U M U M U M U M U M U + -
ECA1 ECA/H8 EAH3 EH1 N [CM ECAAi3 EAH1 EH1 N 
hMLH-1 ATM 
I ^ H B U B B B B f l S B D H S m 
M U M U M U M U MU M U - * - - - M U M U M U M U M U M U + - -
ECA12 ECA/H4 EAH4 EH2 N ECA14 ECA/H2 EAH1 EH2 N 
PTEN HIC~1 
M U M U M U M U M U M U + - - M M MM M M + -
ECA7 ECA/H5 EAH2 EH5 N 印灿 以 … “ 
ECA/H2 EH1 
Fig.5.1. MSP products were shown in gel under UV illumination. 10 markers, APC pl6, 
PRB, hMLH-1, PTEN, E-cad, MGMT, RASSFIA, ATM and HIC-1, were investigated. 
In each marker, 6 cases were shown, there are ECA (Endometrioid adenocarcinoma), 
ECA/H (Endometrioid adenocarcinoma coexisting with hyperplasia and hyperplasia with 
ECA), EAH (Endometrial atypical hyperplasia), EH (Endometrial simplex hyperplasia). 
And the case number also shown. U is amplified with unmethylation primers, whereas M 
is amplified with methylation primers, M bands show methylation. + is positive control, 
IVD was used as template, - is negative control, water was used. 
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Table 5.4. The frequency of methylation in normal endometrium, SCA, EH, EAH and 
ECA, including 6 cases of ECA coexisting with hyperplasia (ECA+H). 
I EH ( n = 2 1 ) | E A H E ^ I E C A E C A ^ H S^ 
(n=21) (n=34) (n=28) (n=6) (n=8) 
E-cad “ 19% 24% 26% 21% 50% 0% 
p l6 19% — 0% 9% 11% m 0% 
hMLHl - 48% 33% 4 4 % 3 9 % 67% 0% 
^ S S F I A 29% 67% 35% 39% 17% 0% 
APC “ 5% 10% 12% 7% ^ 0% 
PRB 10% 33% 15% 78% 0% 0% 
PTEN “ 43% — 14% 0% 0% 0% 0% 
HICl _ 0% ~~38% 9 % ~ ~ 11% 0% 0% 
ATM — 0% 52% 1 5 % ~ 11% 33% 0% 
MGMT _ 14% 19% 21%~~ 21% 17% 0% 
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Fig. 5.3. Summery of methylation of tumor suppressor genes in ECA which can be 
divided into 2 groups. They are ECA coexisting with hyperplasia (ECA+H) and ECA 
without coexisting with hyperplasia. 
Table 5.5. The correlation between promoter hypermethylation and staging. 
No significant correlation is found. 
. S � E T o t a 7 ~ 1 
1 2 3 
0 2 1 " 0 3 
1 5 2 3 10 
No. of genes 2 7 2 2 1\ 
methylated 3 5 0 — 4 9 
4 1 0 0 1 
Total I 20 I 5 I 9 I 34 
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Table 5.6. The correlation between promoter hypermethylation and grading. 
No significant correlation is found. 
GRADE 
——1 2 I 3 Total 
0 0 2 1 3 
1 6 1 3 一 10 
No. of genes 2 — 7 3 1 11 
methylated 3 _ 5 2 2 9 
4 1 0 0 1 
Total I 19 I 8 I 7 I 34 -
Promoter methylation on endometrial cancer cell lines 
Gene promoter methylation of ten candidate tumor suppressor genes were investigated in 
endometrial cell lines RL-95 and KLE. The results were shown in table 5.7. Promoter 
methylation is frequent in endometrial cancer cell lines. 
Table 5.7 Methylation data on endometrial cell lines. +Partial Methylation; -H-Complete 
Methylation; -No methylation. 
Cell lines I Ecad pl6 I hMLHl I RASSFIA I APC PRB PTEN HICIl ATM I MGMT I MI 
RL-95 ^ - ^ + + ++ + + + - + 0.7 
KLE - - + ++ + 0 . 3 
5.3 MSI analysis: 
ECA was classified as MSI positive (MSI +ve) when at least 1 of the 7 markers exhibit 
instability. In our study, the markers are BAT-25(4ql2), BAT-26(2pl6), BAT-40, 
D2S123(2pl6-p21), D5S346(5q21-q22), D17S250(17ql 1.2-ql2), TGFb2R. MSI+ were 
divided into MSI-High and MSI-Low. When 2 of the 7 markers or above show instability, 
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it is MSI-High. If only 1 marker show instability, it is MSI-Low. The MSI results were 
shown in fig.5.4, and the MSI status of individual markers in individual cases were 
shown in table 5.8. 
In 34 cases of endometrial cancer, twenty-six cases (76.5%) were microsatellite stable 
(MSS), 8 cases (23.5%) were MSI positive. Among the MSI positive cases, 4 cases were 
MSI-low and 4 cases were MSI-high. The presence of MSI was correlated with higher 
grade (spearman p=0.014) (table 5.9) and higher stage (spearman p=0.010) (table 5.10). 
Interestingly, the MSI status does not correlate with the methylation status of hMLH-1 in 
this series. The hMLH-1 methylation status, methylation index (MI) and the MSI status 
of individual cases were shown in table 5.12. The mean MI was 0.21 for MSS cases and 
0.11 for MSI positive cases. MSS cases has significantly higher MI than MSI positive 
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Fig.5.4. The analysis of MSI. MSI- microsatellite instability+; MSS- microsatellite stable. 
Example case number shown in the boxes. 
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Table 5.8. The MSI of individual marker in individual patient. +MSI+; - MSS. 
CA+H Grade Age D5S346 D2S123 BAT40 BAT25 BAT26 D17S250 \ TGFb2R M+ 
6 1 ^ 七 -A -J2 -J- -j- -I- 0/0 
I 1 38 ^ ^ -/- -/- -/- -I- -/- 0/0 
2 1 ^ -/- -J- -J2 -J2 -J2 -Jz -Ji 0/0 
3 1 ^ -J- -Jh ^ -J- -J- -J- -J- 0/0 
4 1 ^ 土 -/- 七 -/- -/- -I- +/- 1/0 
5 1 ^ -J2 -J2 -Ji 'Ji di 七 zh 0/0 
CA Grade Age DSS346 D2S123 BAT40 BAT25 BAT26 D17S250~ TGFb2R M+ 
7 1 62 _ - - - - 0 
8 1 59 - - - - - - - 0 
9 1 75 - ： - - - - - 0 
10 1 68 - - - + - - - 1 
II 1 65 - - - - - 0 
12 1 70 - - - - - - - 0 
13 1 53 - : ： ： ： ： ： 0 _ 
14 1 48 - - - - - - 0 
15 1 52 ： ： -- ： ： ： ： 0 
16 1 ^ - - - - - - - 0 
17 1 41 - - - - - - 0 
19 1 49 - - - - - - - 0 
18 1 32 - - - - - - 0 
2 5 2 47 - ： ： ： ： ： - 0 
2 6 2 53 - - - ： ： ： ： 0 
2 7 2 49 - - - - - : 0 
20 2 62 + - + - - ： + 3 
21 — 2 52 - - - - - ： + 1 
22 — 2 51 - ： ： ： ： ： - 0 
23 2 62 ： ： ： ： ： - 0 
24 2 55 ： ： ： ： ： - 0 
29 3 76 - ： + + ： ： + 3 
30 — 3 52 _ - _ - - - ： ： - 0 
31 3 53 - - - — - - ： - 0 
32 3 54 - ： + + ： ： - 2 
33 ~ 3 71 - - - 一 - - ： + 1 
34 3 67 " - — - - ： ： - 0 
28 3 49 ： ： ： + t - 2 
SCA ~Grade Age D5S346 D2S123 BAT40 BAT^ BAT26 D17S250 TGFb2R M+ 
1 3 58 - - — - - — - ： - 0 
2 3 56 一 - _ - — - - 一 - ： - 0 
3 — 3 52 - — - - — - - ： - 0 
4 3 66 - - - - - ： ： 0 
5 3 70 - - - - ： ： ： 0 
6 3 72 - - - - ： ： ： 0 
7 3 69 - - - - - - - 0 
8 3 I 59 I - - I - I - I - I - - 0 
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Table 5.9. Correlation between MSI and grading of EAC. (Spearman p=0.014) 
Grade 
Total 
1 2 3 
1 MSS 16 7 3 I 26 ~ 
MSI status MSI-low 2 1 } 4 
PMSI-high I 0 I 1 3 4 
Total 18 9 7 34 
Tables. 10. Correlation between MSI and staging of EAC. (Spearman p=0.010) 
r i _ r ^ r 
r 1 2 3 
^ “ I 19 2 — 5 26 
MSI status MSI-low 2 1 1 4 
[ M S I - h i g h 0 1 3 ^ 
“ Total [ 2 l 4 9 M 






Table 5.12. Summery of methylation index (MI) calculated from 10 markers, hMLH-1 
methylation status and MSI status. For cases of endometrioid adenocarcinoma with co-
exist endometrial hyperplasia, both ECA and EH were investigated the results were listed 
as carcinoma / hyperplasia.(hMLH 1 :-unmethylated, +methylated; MSI: - MSS, +MSI) 
Stage Grade CA+H MI hMLH-1 MSI 
IB 1 1 0.3/0.5 — -/+ -/-
IB — 1 — 6 “ 0.1/0.1 +/- -/-
“ LA 1 " 2 0.3/0 ~ +/- - / - — 
IB ~ 1 — 3 “ 0.2/0 +/- -/-
~ 3A " 1 4 0.2/0.1 -/- +/-
IC ~ 1 一 5 - 0.2/0.4 +/+ -/-
“ S t a g e Grade “ CA MI hMLHl MSI _ 
IB " 1 " 7 0.2 - -
— I C — 1 — 8 “ 0.1 - -
IB ‘ 1 9 0.1 ： -
IB - 1 ~ 10 0.1 - -
— IB - 1 “ 11 0.1 - -
- IB 1 12 0.3 + -
IB - 1 13 0.2 - -
2B 1 18 0.2 ： -
lA ~ 1 — 14 0.3 + -
IB - 1 15 0.4 + -
2B ~ 1 — \6 OJ ： -
一 3C _ 1 _ 17 0.3 + -
LA " 1 19 0.2 - -
3C ~ 2 20 0.1 ： + 
IB ~ 2 ~ 21 0 ： + 
IB 2 " 22 0.2 - -
3C ‘ 2 23 0.3 + -
IC " 2 24 0 ： -
IB 2 “ 25 0.3 + -
3C 2 26 — 0.2 + -
2B “ 2 27 0.2 ： -
2B " 3 ' 28 0.1 _ + -
3A 3 — 29 0.3 + + 
3C 3 30 03 + -
IB 3 _ 31 0.2 + -
3A 3 “ 32 — 0.1 - -
2B 3 33 0 ： + 
3A “ 3 34 0.1 ： -
Stage — Grade SCA MI hMLHl MSI 
— 2 B 3 1 0.1 -
3C " 3 " 2 ^ + -
2A 3 “ 3 — 0.2 - -
3A - 3 4 ~ 0.2 ： -
SC 3 5 — 0.2 + -
2A ‘ 3 6 0.3 + -
2B 3 7 — 0.2 ： -
— 3 C I 3 I 8 I 0.2 I + I 
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Chapter 6 Discussion 
6.1 Promoter hypermethylation in endometrial cancer 
DNA methylation is an epigenetic event that is regarded as an alternative mechanism for 
inactivation of tumor related genes. Promoter hypermethylation had been discovered in 
multiple tumor suppressor genes in different malignancies and considered playing an 
important role in carcinogenesis (Baylin and Herman, 2000). In this part of study, we 
have examined the promoter hypermethylation of 10 candidate tumor suppressor genes in 
endometrial cancer (ECA) and its precursor lesions, endometrial hyperplasia with atypia 
and without atypia. The study provides comprehensive analysis of gene promoter 
methylation profiles in endometrioid adenocarcinoma and its precancerous lesion. 
In this study, ten markers were selected in methylation detection. They are E-cad, pi6， 
MGMT, APC, hMLH-1, ATM, HIC-1, RASSFIA, PRB and PTEN. They are tumor 
suppressor genes and they are commonly used as markers in methylation analysis 
because they are frequently methylated in different tissue cancer types. Tumor suppressor 
genes play active roles in apoptosis, cell cycle regulation or DNA mismatch repair. All 
these function is important, tumor suppressor gene inactivation is important in 
carcinogenesis in many different types of cancer. 
In this study, methylation-specific PCR (MSP) was selected to detect the methylation in 
tumor samples. The reasons we choose MSP is that MSP is very specific and sensitive 
method and it is relatively simple. Comparing to other methods such as combined 
bisulfite restriction analyses (COBRA) which is commonly used, COBRA need 
restriction enzyme, its creation and modification is critical in the experiment. However, 
MSP do not need restriction enzyme, so these problem do not occur, also the incomplete 
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digestion do not appear. On the other hand, other methods such as bisulfite sequencing 
and southern blotting analysis were not selected in our study. Since our EC samples are 
paraffin-embedded tissue，DNA extracted from paraffin-embedded tissue is just small 
amount and the quality is not good enough to employ bisulfite sequencing and southern 
blotting analysis. Therefore, we employed MSP as detection in our study. MSP can be 
performed with small amount of DNA, and DNA extracted from paraffin-embedded 
tissue is good enough to perform MSP because MSP is highly sensitive and specific. 
6.1.1 Concurrent hypermethylation of multiple genes in endometrioid 
adenocarcinoma and its precursor lesions. 
In this study, promoter hypermethylation of tumor suppressor genes is frequently 
detected in endometrioid adenocarcinoma. Thirty four cases of endometrioid 
adenocarcinoma (ECA) were examined, 91% of ECA demonstrated gene methylation in 
at least one of the 10 candidate tumor suppressor genes. 59% of ECA demonstrated 
hypermethylation in more than one genes and 26% of ECA demonstrated 
hypermethylation in 3 or above genes. Methylation indexes (MI) were calculated and the 
mean MI of 10 genes in ECA is 0.19. None of the normal control had hypermethylation 
detected. Thus, gene promoter hypermethylation appears to be common event in 
endometrioid adenocarcinoma. 
Endometrial hyperplasia is considered as pre-cancerous lesion of ECA. In our study, we 
examined both endometrial hyperplasia with and without cytological atypia. It appears 
that gene methylation is also common in endometrial hyperplasia. The methylation index 
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for endometrial hyperplasia without atypia (EH) and with atypia (EAH) are 0.20 and 0.29 
respectively. There are no statistical significant difference in promoter hypermethylation 
among ECA, EAH and EH. In this study, both precancerous lesions and carcinomas show 
promoter methylation. This finding suggested that gene promoter hypermethylation are 
more likely to be involved in the early events in development of ECA. 
6.1.1.1 Promoter hypermethylation of E-cadherin 
Methylation of E-cadherin (E-cad) gene has been widely reported in different tumors 
(Bomman, et al, 2001; kanai, et al., 1997; Nass，et al., 2000). E-cadherin belongs to a 
class of cell adhesion molecules (CAM) and is important for tissue integrity, cell 
movement and morphogenesis (Gumbiner, 1996). Loss of function of E-cad was strongly 
associated with tumor invasion (Birchmeier and Behrens, 1994). Saito T, et al. 
demonstrated that gene promoter hypermethylation of E-cad is associated with grading 
and the metastasis level of endometrial carcinoma (Saito T, et al, 2003). In this study, the 
methylation frequency of E-cad in EH, EAH and ECA are 19%, 24% and 26% 
respectively, but not detected in normal endometrium. Frequent methylation of E-cad in 
ECA was demonstrated, and it is consistent with others' previous studies. 
6.1.1.2 Promoter hypermethylation of APC 
Adenomatous polyposis coli (APC) gene is located on chromosome 5q21. APC is a 
tumor suppressor gene to form complex with Axin and GSK3 in the Wnt signaling 
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pathway to inactivate -catenine by promoting its degradation. Loss of function of APC 
protein resulted in stabilization of jS -catenine within the cell. Accumulation of /5 -
catenine eventually leaded to the formation of complexes with DNA binding proteins T-
cell factor (Tcf) and lymphoid enhancer-binding factor (Lef-1) which translocated into 
the nucleus and activated specific gene. Loss of function of APC by genetic mechanism 
was common in cancer (Fodde, et al , 2001). Epigenetic mechanism was also found to 
involve in the gene inactivation in many cancers (Brabender,et al., 2001, Maruyama, et al, 
2001; Virmani, et al, 2001; Zysman, et al, 2002). Promoter hypermethylation methylation 
can silence gene as same as the results of loss of function mutation, however, this gene is 
not permanent silence. In this study, the methylation frequency of APC in EH, EAH and 
ECA are 5%, 10% and 12% respectively. However, previous studies showed that 
methylation frequency of endometrial cancer is from 43% to 46.6%, and the methylation 
frequency of endometrial hyperplasia is about 17%. Comparing to others' previous 
studies, the methylation frequency detected in this series of endometrial cancer and its 
precursor lesions are lower than that found in others' studies. Nevertheless, APC 
promoter hypermethylation occur in both ECA and its precancerous lesions, endometrial 
hyperplasia and endometrial atypical hyperplasia. APC promoter methylation in 
endometrial cancer appears to be an early event in carcinogenesis of endometrial cancer. 
6.1.1.3 Promoter hypermethylation of MGMT 
The DNA repair protein 0^-methylguanine DNA methyltransferase (MGMT) removes 
alkyl adducts from the O^ position of guanine in DNA. Failure to remove the alkyl 
adducts generate G:C to A:T transition mutation and promote tumorgenesis as 
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demonstrated (Esteller, et a l , 2001). MGMT which located at 10q26, is frequently 
hypermethylated in human cancers resulting in loss of expression (Bae, et al, 2002， 
Esteller, et al, 2002, Oue, et al, 2001). There is no previous study of endometrial cancer 
investigated for MGMT gene promoter methylation. In this study, we investigated the 
promoter methylation of MGMT as a new marker in endometrial cancer, the promoter 
methylation frequency of MGMT detected in EH, EAH and ECA are 14%, 19% and 21% 
respectively. It is a new finding indicated that MGMT gene promoter methylation is 
common in endometrial cancer, and it may be an early event in endometrial cancer 
development. The significance of the biological effect needs further investigation. 
6.1.1.4 Promoter hypermethylation of RASSFIA 
RASSFIA is located in 3p2L RASSFIA was isolated as a tumor suppressor gene in this 
region from a two-hybrid screen (Dammann, et al., 2000). One of the slice variants of the 
gene RASSFIA undergoes frequent epigenetic changes in tumors of lungs, nasopharynx, 
breast, kidney, stomach, ovary and urinary bladder (Agathanggelou, et a l , 2001; Burbee, 
et al, 2001; Byun, et al, 2001; Dreijerink, et al, 2001; Lee, et al, 2001; Lo, et a l , 2001; 
Yoon, et al., 2001). Although the functions of RASSFIA are not completely understood, 
several studies found that it can reduce tumor growth both in vitro and in nude mice 
model (Burbee, et al, 2001; Dreijerink, et a l , 2001; Vos，et al, 2000). Those experiments 
suggested that it was a candidate tumor suppressor gene. Structural analysis also found 
that its RAS-association domain likely in the RAS-mediated apoptotic mechanism. 
RASSFIA was also showed to bind with NOREl, the novel RAS effecter and MSTl, the 
pro-apoptotic protein kinase in mediating the apoptotic effecter of RAS (Khokhlatchev, et 
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al, 2002; Ortiz-Vega, et al, 2002). There is no previous data on the methylation status of 
RASSFIA in endometrial cancer. In this study, we investigated；the promoter methylation 
of RASSFIA as a new marker in endometrial cancer. Promoter hypermethylation was 
detected in EH, EAH and ECA in 29%, 67% and 35% respectively, but not in normal 
endometrium. High methylation frequencies were detected in RASSFIA in both cancer 
and its precursor lesions, endometrial hyperplasia were demonstrated. Also, complete 
promoter hypermethylation was detected in both 2 endometrial cancer cell lines, RL-95 
and KLE. This new findings indicated that RASSFIA promoter methylation is common 
in endometrial cancer and its precursor lesions. Promoter hypermethylation are more 
likely to be involved in an early event in cancer development in endometrial cancer. 
6.1.1.5 Promoter hypermethylation of hMLH-1 
hMLH-1 is a DNA mismatch repair gene located on human chromosome 3p21. In 
previous study in endometrial cancer, 54% cases of ECs showed promoter methylation. 
Among methylated ECs, 42% contained methylated promoters in adjacent normal. In this 
study, promoter hypermethylation of hMLH-1 was detected in EH, EAH and ECA in 
48o/o，33% and 44% respectively. High methylation frequencies were detected in hMLHl 
in both carcinoma and its precursor lesions, hyperplasia. hMLH-1 promoter 
hypermethylation is common in endometrial cancer and its precursor lesions. It is more 
likely to be involved in an early event in cancer development in endometrial cancer. This 
results is consistent with others' previous studies. 
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6.1.1.6 Promoter hypermethylation in ECA coexisting with hyperplasia and not 
coexisting with hyperplasia 
By comparing the ECA coexisting with hyperplasia and not coexisting with hyperplasia, 
the methylation status of individual genes and overall methylation index appear different, 
and the significant differences in methylation pattern detected in current study cannot be 
found. Thus, there is no significant differences found in this series of EGAs. 
6.1.2 Promoter hypermethylation in serous adenocarcinoma (SCA) 
Interestingly, none of the serous adenocarcinoma demonstrated any gene methylation in 
our study. Although the numbers of serous adenocarcinoma is small, the results suggest 
that gene methylation is rare in serous adenocarcinoma. 
In previous studies, results showed there are differences in genetic and molecular 
alterations between these 2 types of carcinoma, endometrioid and non-endometrioid 
adenocarcinoma. The carcinogenic pathway of these 2 types of carcinomas seen to be 
different. (D Tritz, 1997; Berchuck A.，1997) 
In addition, previous study showed that both frequency and patterns ofLOH differed 
greatly between the two tumor types. Loss of heterzygosity (LOH) was frequently 
detected in the non-endometrioid adenocarinomas, but it was rare in the endometrioid 
adenocarinomas. (D Tritz, 1997) Therefore, it is hypothesis that carcinogenesis of ECA is 
due to epigenetic alterations such as gene promoter hypermethylation, but it is not due to 
genetic changes. However, SCA is non-endometrioid adenocarcinoma, the carcinogenesis 
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of SCA is seem to be due to the genetic alterations such as LOH and deletion, but it is not 
due to methylation. All these findings supported the hypothesis that carcinogenetic 
pathways are distinct between endometrioid and serous adenocarcinoma. (D Tritz, 1997; 
Berchuck A., 1997) In our study, the results is consistent with others' previous studies. 
6.2 Microsatellite status analysis 
Microsatellites are DNA tandem repeat sequences found throughout the genome. 
(Eshleman J.R., 1996) These sequences show variation between individuals (Weber and 
May, 1989) and can be used as markers in genetic analysis. Microsatellite instability 
(MSI) can be detected by the change of any length in these repetitive sequences due to 
insertion or deletion in tumor tissue as compared to that in normal tissue. It was 
recognized that the patterns of microsatellites are unstable in certain tumors. 
6.2.1 MSI in endometrial cancer 
Many studies found MSI has significant role in carcinogenesis in stomach, colon, lung, 
breast and prostate (Caldes, et a l , 2000; Hayden, et al., 2000; Perinchery, et al” 2000; 
Yamashita, et al., 2000). It was also identified in 17 to 43% of endometrial carcinomas. 
(Wallace, 1998; Horii, 1992; Itoh, 1994; Hattori，1996; Akimoto, 1998; Taniguchi, 1998) 
In this study, MSI positive was detected in 23.5% of ECA, while 76.5% of ECA were 
microsatellite stable (MSS). This result is consistent with the previous studies. 
Microsatellite instability is quite common in endometrial cancer. 
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In our study, the presence of MSI was higher in higher grade ECA (Spearman p=0.014) 
and higher stage ECA (Spearman p=0.010). This result demonstrated that the MSI 
positive cases correlate with pathological grading and staging of ECA. It is consistent 
with previous that MSI was correlated with histological grade, International Federation of 
Gynecologists and Obstetricians (FIGO) stage, and also myometrial invasion, and 
lymphonode metastasis. (Hirasawa A, 2003) The prognostic implications of MSI status in 
patients with ECA deserve further investigation. However, it is different from other tissue 
type of cancers such as colorectal cancer. Previous studies showed that MSI+ sporadic 
colorectal cancers were associated with poor differentiation and less frequent systemic 
metastasis than MSI- tumors. MSI+ status (p=0.038) were independent favorable 
prognostic factors for survival in sporadic colorectal cancer patients. (Lim SB, 2004) So 
the results detected in this study in endometrial cancer inverse with previous colorectal 
cancers studies, it is unexpected. Therefore, different tissue types of cancers show 
different molecular characteristics, and different types of cancer seem to be due to 
different carcinogenic pathways. So prognostic implications of MSI status deserve further 
investigation. 
6.2.2 MSI and concurrent promoter hypermethylation 
Methylation index (MI) was calculated in relation to the MSI status. The mean MI of 
ECA was 0.21 for MSS cases and 0.11 for MSI positive cases. MSS cases had 
significantly higher MI than MSI positive cases (Mann-Whitney U p=0.028). This 
finding suggests that MSI positive and MSS cases may have different distinct 
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carcinogenic pathways in ECA. The possible underlying explanation is unknown and 
deserve for further investigation. 
6.2.3 MSI and promoter hypermethylation of hMLH-1 
In previous study, inactivation of the MLHl gene may occur via epigenetic changes in a 
large fraction of MSI + cancers, such as DNA methylation of MLHl transcriptional 
regulatory sequences. (Leung S.Y., 1999; Cunningham J.M., 1998; Herman J.G., 1998; 
Kane M.F., 1997; Markowitz S.，1995) However, MSI status was not always correlated 
with hMLHl gene promoter hypermethylation. (Poala Baldinu, Cancer, 2002; Whelan AJ, 
2002) It is consistent with our study that MSI is not correlated with hMLH-1 promoter 
methylation. Thus, there may also be other mechanism(s) that associated with 
microsatellite instability. 
80 
Chapter 7 Conclusion 
1. Our study demonstrated gene promoter methylation is a common event in 
endometrioid adenocarcinoma but not in serous adenocarcinoma. Relatively high 
frequency of gene promoter methylation was detected in hMLHl, RASSFIA, E-cadherin 
and MGMT genes. The frequent methylation of RASSFIA and MGMT genes represent 
new observations and deserve for further investigation. 
2. Gene promoter methylation in multiple genes also commonly observed in endometrial 
hyperplasia. The findings suggested that gene methylation may be an early event in 
carcinogenesis of endometrioid adenocarcinoma. 
3. Microsatellite instability (MSI) is detected in a subset of endometrial adenocarcinoma. 
The MSI status is correlated with tumor grade and stage. 
4. Interestingly, MSI is inversely correlated with frequency of gene promoter methylation. 
Microsatellite stable (MSS) cases had significantly higher MI than MSI positive cases. 
The observations suggested that ECA with or without MSI have distinct patho-biological 
features. The findings may have implications in understanding of carcinogenic pathways 
in endometrial cancer. 
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Further studies 
Our study indicated that gene promoter methylation is common in both endometrioid 
adenocarcinoma and the precancerous lesion, endometrial hyperplasia. Other epigenetic 
alterations, like histone acetylation may also be involved. Thus, future histone acetylation 
analysis may need to be investigated. We observed the frequent RASSFIA and MGMT 
gene methylation in our study. The cellular pathways that may be disrupted are of interest 
and deserve further investigations. Since gene methylation is commonly detected in ECA 
and endometrial hyperplasia, it opens the possibility of using gene methylation as 
markers for endometrial pathology. Our findings also support the prognostic significance 
of MSI status in ECA. However, the clinical usefulness of MSI status as prognostic 
marker required a larger scale study to determine. Moreover, microsatellite stable (MSS) 
cases had significantly higher MI than MSI positive cases. The observations suggested 
that ECA with or without MSI have distinct patho-biological features. However, the 
underlying mechanism that link up the MSI and methylation status remained unexplained. 
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